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 Abstract
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Apicomplexan infections cause substantial morbidity and mortality, worldwide. New, improved therapies are needed.  Herein, we
create a next generation anti-apicomplexan lead compound, JAG21, a tetrahydroquinolone, with increased sp3-character to
improve parasite selectivity. Relative to other cytochromeb inhibitors, JAG21 has improved solubility and ADMET properties,
without need for pro-drug. JAG21 significantly reduces Toxoplasma gondii tachyzoites and encysted bradyzoites in vitro, and in
primary and established chronic infections in vivo.  Moreover, JAG21 treatment leads to 100% survival.  Further, JAG21 is
efficacious against drug-resistant Plasmodium falciparum in vitro. Causal prophylaxis and radical cure are achieved after P.
berghei sporozoite infection with oral administration of a single dose (2.5mg/kg) or three days treatment at reduced dose
(0.625mg/kg/day), eliminating parasitemia and leading to 100% survival. Enzymatic, binding, and
co-crystallography/pharmacophore studies demonstrate selectivity for apicomplexan relative to mammalian enzymes. JAG21 has
significant promise as a pre-clinical candidate for prevention, treatment and cure of toxoplasmosis and malaria.
  
 Contribution to the field
We find that JAG21 is effective against actively replicating T.gondii tachyzoites, and previously untreatable chronic encysted
bradyzoite brain stage in vitro , and in mice. We demonstrate JAG21’s synergy with a cytochrome b/c qo inhibitor atovaquone
against tachyzoites. JAG21 also is effective in vitro against drug susceptible and known drug resistant forms of P. falciparum.
JAG21 is effective as causal prophylaxis and definitive cure in a single oral dose of 2.5mg/kg for P.bergheii murine malaria. JAG21
inhibits both Toxoplasma and Plasmodia cytochrome b qi and has ADMET properties suitable to become a medicine for people. We
prove JAG21’s mechanism of action, using enzymology, binding assays, co crystallography and co cryo-electron microscopy. We
discover how it might be further improved, if this were needed. We demonstrate safety and efficacy against T. gondii tachyzoites
and previously untreatable latent bradyzoites, the form of the organism that is present in the brain of 2 billion people worldwide,
lifelong, and against plasmodia. JAG21 treatment of conditional mutant deltaRPS13 and transcriptomics define a metabolically
quiescent “persister”,“stasis” state that is reversible even after substantial periods of dormancy,. This contributes to conceptual
and functional understanding of both Plasmodia and Toxoplasma infections and molecular mechanisms whereby “persisters” might
be eliminated. Moving toward addressing this question, optimizing treatment , and identifying co-administered companion
compounds that may lead to definitive cure for human infections, we created a stable nanoformulated JAG21. Using this new
formulation, we determined that oral administration of JAG21 reduces parasite burden after infection of mice with a highly
virulent strain of T.gondii.
  
  
 Funding statement
 
This work was supported by NIAID NIH DMID U01 AI082180 and the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) Grant #5T35DK062719-28 to FE. This was also supported by National Institutes of Health (NIH) contract number
HHNS272200900007C, NIH. National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIAID) award
numbers R01AI071319(NIAID) and  R01AI027530 (NIAID) ;NIAID contract Number HHNS272200900007C; MIAID award number
I revi
ew
U19AI110819: NIAID award number U01 AI077887(NIAID) and Defense Threat Reduction Agency award number 13-C-0055, and
Department of Defense award numbers W911NF-09-D0001 and W911SR-07-C0101.  We thank and gratefully also acknowledge the
support of the Cornwell Mann family, the Ramirez, Musillami, Quinn, Rosenthal, Greenberg, Morel, Rooney and Engel families, Taking
out Toxo, and The Toxoplasmosis Research Institute. The work also was supported by the Bill and Melinda Gates Foundation (BMGF,
OPP1150755). This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under
Grant No. #DGE-1656466 awarded to K.D.R.
  
 Ethics statements
 Studies involving animal subjects
Generated Statement: The animal study was reviewed and approved by This study was carried out in accordance with regulations
of The University of Chicago IACUC and IBC and of The Home Office of the UK Government under the Animals [Scientific Procedures]
Act 1986. All work in the UK with mice was covered by License PPL60/4568, Treatment and Prevention of Toxoplasmosis with
approval by the University of Strathclyde ethical review board. .
  
 Studies involving human subjects
Generated Statement: No human studies are presented in this manuscript.
  
 Inclusion of identifiable human data
Generated Statement: No potentially identifiable human images or data is presented in this study.
  
 Data availability statement
Generated Statement: This manuscript contains previously unpublished data. The name of the repository and accession number(s)
are not available.
  
In revi
ew
	 1	
 1 
      Potent tetrahydroquinolone eliminates apicomplexan parasites  2 
 3 
Martin McPhillie1,+ , Ying Zhou2,+, Mark Hickman3,+,++, James Gordon1,++, +,  Christopher R. 4 
Weber2,+,  Qigui Li3, Patty Lee3, Kangsa Amporndanai4, Rachel Johnson1,++, Heather Darby1,  5 
Stuart Woods5, Zhu-hong Li6, Richard S. Priestley7,  Kurt Ristroph8, Scott Biering2, ++ , Kamal El 6 
Bissati2, Seungmin Hwang2++, Farida Esaa Hakim 2, Sarah Dovgin2, ++ Joseph Lykins2, ++, Lucy 7 
Roberts5, ++, Kerrie Hargrave5,++,  Hua Cong1,++, Anthony P. Sinai9,  Stephen P. Muench1, 8 
Jitender Dubey10 , Robert Prud’homme 8, Hernan Lorenzi11, Giancarlo A Biagini7, Silvia N. 9 
Moreno6.* Craig Roberts5, Svetlana Atonyuk4,*, Colin Fishwick1,*, Rima McLeod2,* 10 
 11 
1The University of Leeds, Leeds, UK 12 
2The University of Chicago, Chicago, USA 13 
3Walter Reed Army Institute of Research. USA 14 
4The University of Liverpool, Liverpool, UK 15 
5The University of Strathclyde, Glasgow Scotland, UK 16 
6The University of Georgia, Athens Georgia, USA 17 
7The Liverpool School of Tropical Medicine, Liverpool, UK 18 
8Princeton University, Princeton, New Jersey, USA 19 
9The University of Kentucky College of Medicine, Lexington, USA 20 
10USDA, ARS, APDL, Beltsville, Maryland, USA 21  22 
11J Craig Venter Institute, Rockville, Maryland, USA 23 
 24 
+These authors contributed equally to this work 25 
*To whom Correspondence should be addressed 26 
++Currently at : Charles River UK(JG); Fort Dietrick (MH); University of California at 27 
Berkeley(SB); Monash University, Australia(RJ); VIR Biotechnology. 28 
 (SH); Case Western Reserve University (SD); Medical College of Virginia (JL), Shandong 29 
University(HC);  University of Glasgow (KH) 30 
 31 
Word count:  11,988 original (with edits suggested 13, 643) 32 
Figures 7 33 
In Supplement: 2 Supplemental tables and supplemental text 2 supplental figures 34 
 35 
In revi
ew
	 2	
ABSTRACT 36 
 37 
Apicomplexan infections cause substantial morbidity and mortality, worldwide. New, improved 38 
therapies are needed.  Herein, we create a next generation anti-apicomplexan lead compound, 39 
JAG21, a tetrahydroquinolone, with increased sp3-character to improve parasite selectivity. 40 
Relative to other cytochromeb inhibitors, JAG21 has improved solubility and ADMET properties, 41 
without need for pro-drug. JAG21 significantly reduces Toxoplasma gondii tachyzoites and 42 
encysted bradyzoites in vitro, and in primary and established chronic murine infections.  Moreover, 43 
JAG21 treatment leads to 100% survival.  Further, JAG21 is efficacious against drug-resistant 44 
Plasmodium falciparum in vitro. Causal prophylaxis and radical cure are achieved after P. berghei 45 
sporozoite infection with oral administration of a single dose (2.5mg/kg) or three days treatment 46 
at reduced dose (0.625mg/kg/day), eliminating parasitemia and leading to 100% survival. 47 
Enzymatic, binding, and co-crystallography/pharmacophore studies demonstrate selectivity for 48 
apicomplexan relative to mammalian enzymes. JAG21 has significant promise as a pre-clinical 49 
candidate for prevention, treatment and cure of toxoplasmosis and malaria. 50 
 51 
 52 
Keywords: Toxoplasma gondii, Plasmodium falciparum, Plasmodium bergheii,, cytochrome 53 
b/c Qi domain, inhibitor, SAR, potent lead compound,  JAG21, tetrahyroquinolone,  54 
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cryo-electronmicroscopy, enzyme activity, causal prophylaxis, radical cure, RPS13D, 56 
Plasmodium cynomogoli hypnozoite single cell RNA sequencing,  transcriptomics, stasis form, 57 
tafenoquine, companion compounds, stable nanoformulation, effective treatment 58 
 59 
INTRODUCTION 60 
 61 Malaria	results	in	the	death	of	~0.5	million	children	a	year,	with	drug	resistance	impacting	62 the	 usefulness	 of	 successive	 generations	 of	 new	 medicines	63 ((www.who.int/malaria/publications/world-malaria-report-2017/en/).	 The	 related	64 apicomplexan	parasite,	Toxoplasma	gondii,	is	the	most	frequent	parasitic	infection	of	humans	65 in	the	world.	It	plays	a	significant	role	in	food-born	associated	death	in	the	USA,	destruction	66 of	 the	 human	 retina,	 and	 death	 and	 illness	 from	 recrudescent	 disease	 in	 the	 immune	67 compromised	or	immunologically	immature	(McLeod,	Boyer,	2018).	It	has	been	estimated	68 that	there	are	1.9	million	new	cases	of	this	congenital	T.	gondii	infection	globally	over	a	ten	69 year	period,	causing	12	million	disability	adjusted	life	years	(Torgerson	and		Mastroiacovo,	70 2013)	from	damage	to	the	fetal	brain	and	eye.	Toxoplasmosis	is	an	often	neglected,	untreated	71 or	mistreated	disease.	There	are	approximately	2	billion	people	throughout	the	world	who	72 have	this	parasite	in	their	brain	lifelong,	some	with	known,	severe,	adverse	consequences	73 (Delair et al, 2011;	 Lykins	 et	 al,	 2016;	Wallon	et	 al,	 2013).	There	 are	 possible	 additional,	74 harmful	 effects	 for	 a	 substantial	 number	 of	 chronically	 infected	 people	 as	 this	 parasite	75 modulates	 signature	 pathways	 of	 neurodegeneration,	 motor	 diseases,	 epilepsy,	 and	76 malignancies	(Ngo	et	al,	2017).	No	medicine	eliminates	this	chronic,	encysted	form	of	the	77 parasite.	 New	 and	 improved	 medicines	 are	 greatly	 needed	 to	 cure	 Toxoplasma	 and	78 Plasmodia	infections.	These	parasites	often	share	the	same	molecular	targets	for	medicines	79 due	 to	a	 relatively	 close,	 apicomplexan,	phylogenetic	 relationship	 (McPhillie	 et	 al,	 2016).	80 
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Thus,	 medicine	 development	 for	 each	 of	 these	 parasites	 can	 inform	 development	 of	81 medicines	that	benefit	treating	the	other	(Muench	et	al	2007;		Fomovska et al, 2012). 82 
         One such shared molecular target is the mitochondrial cytochrome bc1 complex that is 83 
important for the survival of apicomplexan parasites such as Plasmodia and T gondii. Cytochrome 84 
b is a subunit of the cytochrome bc1 complex, an inner mitochondrial membrane protein that is 85 
part of the electron transport chain. Activity of this complex is integral to oxidative 86 
phosphorylation and generation of ATP (Vercesi et al, 1998). Cytochrome b activity appears to be 87 
necessary for the replication and persistence of the parasite (McPhillie et al  2016), and is the site 88 
of action of atovaquone (McPhillie et al, 2016).  Cytochrome b is the target for quinolone-based 89 
compounds, but, significant problems with solubility and toxicity have been noted with earlier 90 
cytochrome b inhibitors. In an attempt to design novel quinolone-like inhibitors with improved 91 
solubility, and lower toxicity, compared to known compounds in the literature, we synthesized a 92 
series of tetrahydroquinolinones (THQs). Our preliminary efforts were described in McPhillie et 93 
al ( 2016). We reasoned that the increased ‘sp3’ character of the THQs (i.e. moving from rod-like 94 
to sphere-like 3D space) could provide the required improvement in solubility that would allow 95 
for optimal pharmacokinetic properties. Molecules with an increased percentage of 'sp3 character' 96 
tend to be more three-dimensional, than their planar ('sp2-rich') counterparts. The terms 'sp2' and 97 
'sp3' refer to the shape of their hybridised atomic orbitals, which have trigonal planar and 98 
tetrahedral geometries respectively. Flat aromatic rings ('sp2-rich') are ubiquitous in drug 99 
discovery campaigns, but molecules with more 'sp3 character' are often more specific for their 100 
protein target and can have better physicochemical properties.  Further, we reasoned that the larger 101 
binding pocket in the parasite enzymes (McPhillie et al, 2016), compared to their mammalian 102 
counterparts, would provide room for bulkier substituents to minimize effect on the human 103 
enzyme. Within this new series of compounds, we aimed to identify a mature lead compound with 104 
both anti-Plasmodium and anti-T. gondii activity.  105 
            Our work developed as follows: We recently found markedly increased expression of 106 
cytochrome b in the currently untreatable T. gondii bradyzoite life-cycle stage (McPhillie et al 107 
2016).  Thus, we set out to develop a compound that would inhibit tachyzoites, bradyzoites and 108 
three life cycle stages of even drug-resistant Plasmodia. We sought to do this without a need for a 109 
pro-drug as has been needed in other attempts to target apicomplexan cytochrome b (Frueh et al 110 
2017). Our aim was to improve upon the physicochemical properties of napthoquinones and 111 
endochin-like quinolones (ELQs) targeting cytochrome b, including poor aqueous solubility and 112 
toxicity (McPhillie et al, 2016 ; Khan et al, 1998; Doggett et al, 2012; Capper et al, 2015; Miley 113 
et al, 2015). The intent was further to provide potential solutions for limitations of other 114 
compounds active against apicomplexan parasites (Waxman and Herbert, 1969; Caumes et al, 115 
1995). Our concurrent crystallographic studies also enable better understanding of the interactions 116 
between ligand and the binding pocket of the Qi site  (McPhillie et al,2016). 117 
            Herein, we have identified a preclinical lead candidate based on potent and selective 118 
inhibition of P. falciparum and P. berghei and T. gondii cytochrome bc1 for the treatment of 119 
malaria and toxoplasmosis. The candidate compound demonstrates high efficacy in relevant in 120 
vitro and in vivo models of the diseases, and has considerable potential for broad-spectrum use 121 
(i.e., against T. gondii tachyzoites and encysted bradyzoites and drug resistant Plasmodia). The 122 
data which follow present the creation and characterization of this novel, broad-spectrum, anti-123 
apicomplexan lead compound which has promise for definitive treatment of these infections. 124 
 125 
MATERIALS AND METHODS 126 
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 127 
Syntheses of compounds 128 
 129 
Synthesis of tetrahydroquinolones (THQs) compounds. 130 
The THQ compounds were synthesized at the University of Leeds as described below. 10 mM 131 
stock solutions were made with 100% Dimethyl Sulfoxide (DMSO) [Sigma Aldrich] and working 132 
concentrations were made with IMDM-C (1x, [+] glutamine, [+] 25 mM HEPES, [-] Phenol red, 133 
10% FBS)[Gibco, Denmark]). Compounds are shown in Figure 1A. Final compounds had >95% 134 
purity determined by high performance liquid chromatography (HPLC), high resolution mass 135 
spectrometry and NMR spectrometry. Liquid chromatography-mass spectrometry (LC-MS) and 136 
NMR spectrometry were used to determine the integrity and purity of all intermediates. THQ 137 
compounds were synthesized as described in schemes 1 and 2, which describe compounds 138 
MJM170 and JAG21 as exemplars. Building blocks 1, 8, 9 and 14 were varied to create the 139 
complete series (Figure 1A). 140 
 141 
 
Scheme 1. Synthesis of hit compound 7, also known as MJM170 (McPhillie	et	al	2016). 142 
Synthetic scheme inspired by the route to endochin-like quinolones (ELQs) reported by 143 
Doggett et al, (2012). 144 
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 145 
Synthesis of 2-methyl-5,6,7,8-tetrahydroquinolin-4-one (2) 146 
Platinum oxide (0.100 g, 10 mol %) was added to a solution of 4-hydroxy-2-147 
methylquinoline (1, 1.00 g, 6.28 mmol, 1.00 eq) in glacial acetic acid (10.0 mL). 148 
The heterogeneous mixture was catalytically hydrogenated under a balloon of 149 
hydrogen. After 22 hrs, TLC (10% MeOH–DCM) confirmed complete reaction. 150 
The mixture was filtered through celite under vacuum, washing thoroughly with 151 
EtOAc (50 mL). The filtrate was concentrated and the resulting residue purified by column 152 
chromatography (10% MeOH–DCM) to give the desired product as a pale yellow oil (0.917 g, 153 
5.65 mmol, 89%); Rf 0.14 (10% MeOH–DCM); δH (300 MHz, CDCl3) 1.74-1.76 (4H, m, CH2), 154 
2.29 (3H, s, Me), 2.49-2.52 (2H, m, CH2), 2.67-2.70 (2H, m, CH2), 6.16 (1H, s, Ar-H); δC (125 155 
MHz, CDCl3) 19.0 (Me), 21.8 (CH2), 22.1 (CH2), 27.1 (CH2), 112.5 (CH), 122.4 (Cq), 146.4 (Cq), 156 
147.0 (Cq), 178.3 (Cq); Spectroscopic data consistent with literature values (JMC, 1993, 36, 1245-157 
54). 158 
 159 
Synthesis of 2-methyl-3-iodo-5,6,7,8-tetrahydroquinolin-4-one (3) 160 
nButylamine (6.20 mL, 62.8 mmol, 10.0 eq) was added to a suspension of 2-161 
methyl-5,6,7,8-tetrahydroquinolin-4-one (2, 1.02 g, 6.28 mmol, 1.00 eq) in 162 
DMF (10.0 mL). To this heterogeneous mixture was added I2 (1.60 g, 6.28 163 
mmol, 1.00 eq) in a saturated solution of KI (6.00 mL). After 20 hrs stirring at 164 
R.T., a precipitate formed in the orange solution, excess iodine was quenched 165 
with 0.1 M sodium thiosulfate solution (10.0 mL). The precipitate was filtered by vacuum 166 
filtration, washed with distilled H2O and dried (Na2SO4) to give the desired product as a colourless 167 
solid (1.76 g, 6.09 mmol, quantative yield); δH (300 MHz, DMSO-d6) 1.61-1.70 (4H, m, CH2), 168 
2.29 (2H, t, J 6.0, CH2), 2.43 (2H, s, CH2), CH3 under DMSO peak. 169 
 170 
Synthesis of 2-methyl-3-iodo-4-ethoxy-5,6,7,8-tetrahydroquinoline (4) 171 
Potassium carbonate (1.53 g, 11.1 mmol, 2.00 eq) was added to a heterogeneous 172 
mixture of 2-methyl-3-iodo-5,6,7,8-tetrahydroquinolin-4-one (3, 1.60 g, 5.56 173 
mmol, 1.00 eq) in DMF (15.0 mL), and the reaction heated to 50°C for 30 mins. 174 
The R.B. flask was removed from the heating mantle and ethyl iodide (0.67 mL, 175 
8.33 mmol, 1.50 eq) was added dropwise. The reaction was then heated at 50°C 176 
for 18 hrs. The reaction was cooled to R.T., quenched with water (40 mL). The resulting emulsion 177 
formed which was extracted with EtOAc (50 mL). EtOAc layer were washed with water (3 x 30 178 
mL), brine (3 x 30 mL), dried (Na2SO4) and concentrated to give a pale yellow oil (1.09 g, 3.44 179 
mmol, 61%); Rf 0.88 (1:1 Pet–EtOAc); HPLC (RT = 1.67 mins); LCMS (Method A), (RT = 1.6 180 
min, m/z (ES) Found MH+ 318.0); δH (500 MHz, CDCl3) 1.49 (3H, t, J 7.0, ethoxy CH3), 1.73-181 
1.78 (2H, m, CH2) 1.84-1.88 (2H, m, CH2), 2.78-2.69 (5H, m, CH2 & CH3), 2.84 (2H, t, J 6.5, 182 
CH2), 3.97 (2H, q, J 7.0, OCH2); δC (125 MHz, CDCl3) 15.6 (CH3), 22.3 (CH2), 22.8 (CH2), 23.6 183 
(CH2), 29.3 (CH3), 32.0 (CH2), 68.4 (OCH2), 90.9 (Cq), 124.5 (Cq), 158.3 (Cq), 158.9 (Cq), 163.9 184 
(Cq). 185 
 186 
Synthesis of 2-methyl-3-(4-phenoxyphenyl)-4-ethoxy-5,6,7,8-tetrahydroquinoline (6) 187 
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2-Methyl-3-iodo-4-ethoxy-5,6,7,8-tetrahydroquinoline (4, 0.266 188 
g, 0.839 mmol, 1.00 eq), Pd(PPh3)4 (0.048 g, 0.0419 mmol, 5 189 
mol%) and 4-phenoxyphenylboronic acid (5, 0.270 g, 1.26 190 
mmol, 1.50 eq) were charged to a R.B. flask under N2(g). 191 
Degassed DMF (10.0 mL) was added to the flask followed by 192 
2M K2CO3 (1.60 mL). The flask was heated to 85°C under N2(g). After 15 mins, TLC (4:1 Pet–193 
EtOAc) confirmed reaction was complete. The reaction was cooled and diluted with EtOAc (15 194 
mL), filtered through celite and partitioned between EtOAc (10 mL) and H2O (25 mL). Combined 195 
organics were washed with H2O (3 x 30 mL), then brine (3 x 30 mL), dried (Na2SO4) and 196 
concentrated to give a red oil which was purified by column chromatography (3:1 Pet–EtOAc), to 197 
give the desired product as a pale yellow oil (0.235 g, 0.655 mmol, 78%); Rf 0.31 (3:1 Pet–EtOAc); 198 
HPLC (RT = 3.08 mins); δH (300 MHz, CDCl3) 1.04 (3H, t, J 7.0, ethoxy CH3), 1.76-1.93 (4H, 199 
m, 2xCH2), 2.32 (3H, s, CH3) 2.72 (2H, t, J 6.0, CH2), 2.91 (2H, t, J 6.5, CH2), 3.50 (2H, q, J 7.0, 200 
OCH2), 7.05-7.16 (5H, m, Ar-H), 7.20-7.29 (2H, m, Ar-H), 7.31-7.43 (2H, m, Ar-H); δC (125 201 
MHz, CDCl3) 15.7 (CH3), 22.5 (CH2), 23.0 (CH3), 23.3 (CH2), 23.4 (CH2), 32.7 (CH2), 68.2 202 
(OCH2), 118.6 (CH), 118.9 (CH), 123.4 (CH), 126.8 (Cq), 129.8 (CH), 131.5 (CH), 154.9 (Cq), 203 
156.5 (Cq), 157.1 (Cq), 157.3 (Cq); m/z (ES) (Found: MH+, 360.1973. C24H26NO2 requires MH, 204 
360.1964). 205 
 206 
Synthesis of 2-methyl-3-(4-phenoxyphenyl)-4-ethoxy-5,6,7,8-tetrahydroquinoline (7, 207 
MJM170) 208 
Aqueous hydrobromic acid (>48%) (1.00 mL) was added to a 209 
solution of 2-methyl-3-(4-phenoxyphenyl)-4-ethoxy-5,6,7,8-210 
tetrahydroquinoline (6, 0.226 g, 0.630 mmol, 1.00 eq) in glacial 211 
acetic acid (2 mL). The reaction was stirred at 90°C for 5 days, 212 
monitoring by LMCS. The reaction was cooled to R.T. and the 213 
pH adjusted to pH 5 with 2M NaOH. The precipitate was 214 
collected by vacuum filtration and recrystallized from MeOH:H2O to give the desired product as 215 
an off-white solid (0.155 g, 0.467 mmol, 74%); HPLC (RT = 2.56 mins); δH (500 MHz, DMSO-216 
d6) 1.66-1.72 (4H, m, 2xCH2), 2.08 (3H, s, CH3) 2.31 (2H, t, J 6.0, CH2), 2.56 (2H, t, J 6.0, CH2), 217 
6.99 (2H, d, J 8.5, Ar-H), 7.06 (2H, d, J 7.5, Ar-H), 7.14-7.18 (3H, m, Ar-H), 7.40-7.43 (2H, m, 218 
Ar-H), 11.0 (1H, s, NH); δC (125 MHz, DMSO-d6) 17.7 (CH3), 21.5 (CH2), 21.8 (CH2), 21.9 219 
(CH2), 26.2 (CH2), 117.8 (CH), 118.6 (CH), 121.2 (Cq), 123.3 (CH), 123.7 (Cq), 130.0 (CH), 220 
131.4 (Cq), 132.3 (CH), 142.3 (Cq), 143.2 (Cq), 155.0 (Cq), 156.8 (Cq), 175.4 (Cq); m/z (ES) 221 
(Found: MH+, 332.1654. C22H22NO2 requires MH, 332.1645).  222 
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Scheme 2. Synthetic route to analogues of 7 (MJM170) via route A or route B. Route A is 223 
the original route to analogues but is linear and involves a tricky Suzuki step to 224 
intermediate 12 from intermediates 4 and 10. Route B allows quicker access to analogues 225 
since intermediate 15 can be made in larger quantities and derivatives can be synthesised 226 
via the Chan-Lam reaction to give final intermediate 12 by varying the boronic acid 16. 227 
Synthesis of 1-(4-bromophenyl)-4-(trifluoromethoxy)benzene (10) 228 
Copper (II) acetate (0.435 g, 2.39 mmol, 1.00 eq) was added to a 229 
suspension of 4-bromophenol (8, 0.414 g, 2.39 mmol, 1.00 eq), 4-230 
trifluoromethoxybenzeneboronic acid (9, 0.983 g, 4.79 mmol, 231 
2.00 eq) and 4Å molecular sieves (0.566 g) in DCM (12 mL) at 232 
R.T. A solution of triethylamine (1.7 mL, 11.9 mmol, 5.00 eq) and pyridine (1 mL, 11.9 mmol, 233 
5.00 eq) was added and the reaction was stirred for 16 hrs, open to the atmosphere. After 18 hrs, 234 
the reaction was quenched with 0.5 M HCl (20 mL) and the organic layer washed with water (20 235 
mL), brine (20 mL), dried (Na2SO4) and concentrated to give a red oil which was purified by 236 
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column chromatography (hexane) to give the desired product as a colourless oil (0.582 g, 1.75 237 
mmol, 73%); Rf 0.58 (hexane). 238 
  239 
Synthesis of 2-methyl-3-(4-hydroxyphenyl)-4-ethoxy-5,6,7,8-tetrahydroquinolin-4-one (15) 240 
2-Methyl-3-iodo-4-ethoxy-5,6,7,8-tetrahydroquinoline (4, 0.400 g, 241 
1.26 mmol, 1.00 eq), Pd(PPh3)4 (0.073 g, 0.06 mmol, 5 mol%) and 4-242 
hydroxylphenylboronic acid (14, 0.260 g, 1.89 mmol, 1.50 eq) were 243 
charged to a R.B. flask under N2(g). Degassed DMF (10.0 mL) was 244 
added to the flask followed by 2M K2CO3 (3.00 mL). The flask was 245 
heated to 85°C under N2(g). After 3 hrs, TLC (EtOAc) confirmed reaction was complete. The 246 
reaction was cooled to 50°C, diluted with EtOAc (15 mL) and activated charcoal was added. After 247 
stirring for 30 mins, the mixture was filtered through celite and partitioned between EtOAc (10 248 
mL) and H2O (25 mL). Combined organics were washed with H2O (3 x 30 mL), then brine (3 x 249 
30 mL), dried (Na2SO4) and concentrated to give a brown solid which was triturated with diethyl 250 
ether to give the desired product as a pale red crystalline solid (0.220 g, 0.777 mmol, 60%); Rf 251 
0.22 (EtOAc); m.p. 225-226 °C (EtOAc); δH (500 MHz, MeOD-d4) 7.07 (d, J = 8.6 Hz, 2H, H-3 252 
& 5), 6.86 (d, J = 8.6 Hz, 2H, H-2 & 6), 3.51 (q, J = 7.0 Hz, 2H, CH3CH2O), 2.83 (t, J = 6.3 Hz, 253 
2H, H-8’), 2.72 (t, J = 6.1 Hz, 2H, H-5’), 2.23 (s, 3H, Me), 1.95 – 1.72 (m, 4H, H-6’ & 7’), 1.00 254 
(t, J = 7.0 Hz, 3H, CH3CH2O); δC (125 MHz, MeOD-d4)  164.0 (Cq), 158.1 (C-1), 157.4 (Cq), 255 
156.1 (Cq), 132.2 (C-3 & 5), 129.1 (Cq), 127.9 (Cq), 124.9 (Cq), 116.2 (CH), 69.1 (OCH2), 32.7 256 
(CH2), 23.9 (CH2), 23.4 (CH3), 22.9 (CH2), 22.3 (CH2), 15.7 (CH3); m/z (ES) (Found MH+, 257 
284.1664, C18H21NO2 requires MH, 284.1651). 258 
 259 
Synthesis of 2-methyl-3-(4-hydroxyphenyl)-4-ethoxy-5,6,7,8-tetrahydroquinolin-4-one (12) 260 
1-(4-bromophenyl)-4-(trifluoromethoxy)benzene (10, 261 
0.100 g, 0.30 mmol, 1.00 eq), bis(pinacolato) diboron 262 
(1.10 eq), potassium acetate (3.00 eq) and Pd(dppf)Cl2 263 
(0.03 eq) were added to a oven-dried flask under inert 264 
(N2) atmosphere. Anhydrous DMF (6 mL) was added and 265 
the reaction heated to 80°C under N2 (g). After 22 hrs, the reaction was cooled to R.T., fresh 266 
Pd(dppf)Cl2 (0.03 eq) added, followed by 2-methyl-3-iodo-4-ethoxy-5,6,7,8-tetrahydroquinoline 267 
(4, 0.400 g, 1.26 mmol, 2.00 eq) and 2M Na2CO3 (2.9 mL). The reaction was heated to 80°C for 268 
20 hrs, cooled, diluted with EtOAc (20 mL), filtered through celite and partitioned between EtOAc 269 
(20 mL) and H2O (20 mL). Combined organics were washed with brine (3 x 20 mL), dried 270 
(Na2SO4) and concentrated to give a brown solid which was purified by column chromatography 271 
(3:1 Pet–EtOAc) to give the desired product as a colourless oil (30 mg, 0.07 mmol, 23%); HPLC 272 
(RT = 2.41 mins); δH (500 MHz, acetone) 7.28 (d, J = 8.7 Hz, 2H, H-2’ & 6’), 7.26 (d, J = 9.1 273 
Hz, 2H, H-2’’ & 6’’), 7.09 (d, J = 9.1 Hz, 2H, H-3’’ & 5’’), 7.07 (d, J = 8.7, 2H, H-3’ & 5’), 3.52 274 
(q, J = 7.0 Hz, 2H, CH3CH2O), 2.85 (t, J = 6.5 Hz, 2H, H-8), 2.78 (t, J = 6.2 Hz, 2H, H-5), 2.26 275 
(s, 3H, Me), 1.89 – 1.81(m, 2H, H-7), 1.81– 1.72 (m, 2H, H-6), 0.93 (t, J = 7.0 Hz, 3H, CH3CH2O); 276 
δC (125 MHz, acetone) δ 161.9 (Cq), 157.1 (Cq), 156.5 (Cq), 156.0 (Cq), 154.5 (Cq), 145.3 (Cq), 277 
132.5 (Cq), 132.0 (CH), 126.7 (Cq), 123.0 (CH), 119.8 (CH), 119.0 (CH), 68.0 (OCH2), 32.5 278 
(CH2), 23.0 (CH2), 22.9 (CH3), 22.7 (CH2), 22.5 (CH2), 15.05 (CH3); m/z (ES) (Found: MH+, 279 
444.1792. C25H24F3NO3 requires MH, 444.1781). 280 
 281 
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Synthesis of 2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl)-5,6,7,8-282 
tetrahydroquinolin-4-one (13, JAG21) 283 
Aqueous hydrobromic acid (>48%) (1.00 mL) was added 284 
to a solution of 2-methyl-3-(4-phenoxyphenyl)-4-ethoxy-285 
5,6,7,8- tetrahydroquinoline (12, 30.0 mg, 0.07 mmol, 286 
1.00 eq) in glacial acetic acid (2 mL). The reaction was 287 
stirred at 90°C for 3 days, monitoring by LMCS. The 288 
reaction was cooled to R.T. and the pH adjusted to pH 5 289 
with 2M NaOH. The precipitate was collected by vacuum filtration and recrystallized from 290 
MeOH:H2O to give the desired product as a colourless solid (25.0 mg, 0.06 mmol, 68%); m.p. 291 
>250 ℃; HPLC (RT = 2.78 mins); δH (500 MHz, DMSO-d6) 11.07 (s, 1H, NH), 7.40 (d, J = 8.5 292 
Hz, 2H, H-2’ & 6’), 7.19 (d, J = 8.6 Hz, 2H, H-3’’ & 5’’), 7.13 (d, J = 9.0 Hz, 2H, H-3’ & 5’), 7.02 293 
(d, J = 8.5 Hz, 2H, H-2’’ & 6’’), 2.54 (t, J = 6.0 Hz, 2H, H-8), 2.28 (t, J = 5.9 Hz, 2H, H-5), 2.07 294 
(s, 3H, Me), 1.71 (m, 2H, H-7), 1.65 (m, 2H, H-6); δC (125 MHz, DMSO-d6)  175.7 (Cq), 155.9 295 
(Cq), 154.5 (Cq), 143.5 (Cq), 143.2 (Cq), 142.2 (Cq), 132.5 (CH), 132.2 (Cq), 123.6 (Cq), 123.0 296 
(CH), 121.3 (Cq), 119.6 (CH), 118.2 (CH), 26.2 (CH2), 21.9 (CH2) 21.8 (CH2), 21.5 (CH2), 17.7 297 
(CH3); m/z (ES) (Found: MH+, 416.1492. C23H20F3NO3 requires MH, 416.1473). 298 
 
 299 
Toxoplasma gondii 300 
 301 
Parasite Strains (Isolates) 302 
RH-YFP tachyzoites, (McPhillie et al, 2016; Fomovska et al, 2012; Gubbels et al, 2003), EGS 303 
strain (Vidigal et al 2015; Paredes-Santos et al 2012;McPhillie et al, 2016), Pru-luciferase, Me49, 304 
and RPS13D on the RH strain background (Hutson et al, 2010) were prepared and passaged in 305 
human foreskin fibroblasts [HFF] as described. 306 
 307 
T.gondii in vitro 308 
 309 
In Vitro Challenge Assay for T.gondii  310 
RH strain YFP Tachyzoites 311 
Protocol was adapted from Fomovska, et. al (2012; 2012a) for HFF. HFF were cultured on a flat, 312 
clear-bottomed, black 96-well plate to 90%-100% confluence. IMDM (1x, [+] glutamine, [+] 25 313 
mM HEPES, [+] Phenol red, 10% FBS [Gibco, Denmark]) was removed and replaced with IMDM-314 
C(1x, [+] glutamine, [+] 25 mM HEPES, [-] Phenol red, 10% FBS)[Gibco, Denmark]). RH-YFP, 315 
lysed from host cells by passing twice through a 27-gauge needle, were counted, then diluted to 316 
32,000/mL in IMDM-C. HFF were infected with 3200 RH-YFP, then returned to 37° C, CO2  (5%) 317 
incubator for 1-2 hours for infection. Various concentrations of the compounds in 20 µl IMDM-C 318 
were added to each well. There were triplicates for each condition. Controls were 319 
pyrimethamine/sulfadiazine (standard treatment), 0.1% DMSO only, HFF only, and untreated 320 
cultures of HFF infected with  2 fold dilutions of YFP expressing  parasites (called “YFP gradient” 321 
to establish amount of color from known numbers of YFP expressing parasites). Cells were 322 
incubated at 37° C for 72 hours. Plates were read using a fluorimeter (Synergy H4 Hybrid Reader, 323 
BioTek) to ascertain amount of relative fluorescence units (RFU) YFP, to measure parasite burden 324 
after treatment. Data were collected using Gen5 software with IC50 calculated by graphical analysis 325 
in Excel. 326 
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 327 
An initial screening assay of 10 µM, 1µM, 100 nM, and 10 nM of the compounds was performed. 328 
Compounds were not considered effective or pursued for further analysis if there was no inhibition 329 
of tachyzoites at 1µM. If compounds were effective at 1 µM, another experiment was performed 330 
to assess effect at 1 µM, 500 nM, 250 nM, 125 nM, 62.5 nM, and 31.25 nM.   331 
 332 
Cytotoxicity Assays in parallel with  RH Strain T.gondii in vitro studies 333 
Toxicity assays used WST-1 cell proliferation reagent (Roche) as in Fomovska, et. al.(2012). HFF 334 
were grown on a flat, clear-bottomed, black 96-well plate. Confluent HFF were treated with 335 
inhibitory compounds at concentrations of 10 µM and 50 µM. Compounds were diluted in IMDM-336 
C, and 20 µl were added to each designated well, with triplicates for each condition. A gradient 337 
with 2 fold-decreasing concentrations of DMSO from 10% to 0% in colorless, translucent IMDM-338 
C was used as a control.  The plate was incubated for 72 hours at 37° C.  10 µl WST-1 reagent 339 
(Roche) were added to each well. Cells were incubated for 30-60 minutes. Absorbance was read 340 
using a fluorimeter at 420 nm. A higher degree of color change (and absorbance) indicated 341 
mitochondrial activity and cell viability. 342 
 343 
In vitro Challenge Assay for EGS strain Bradyzoites 344 
HFF cells were grown in IMDM on removable, sterile glass cover slips in the bottom of a clear, 345 
flat-bottomed 24-well plate.  Cultures were infected with 3x104 EGS strain parasites per well, in 346 
0.5 mL media. The plate was returned to incubator at 37° C overnight. The following day, the 347 
media was removed. Colorless IMDM and compounds were added to make various concentrations 348 
of the drug. Total volume was 0.5 mL  2 wells had media only, as a control.  Plates were returned 349 
to the 37° C incubator for 72 hours, checked once each 24 hours. If tachyzoites were visible in the 350 
control before 72 hours, cells were fixed and stained. 351 
  352 
Cells were fixed using 4% paraformaldehyde and stained with Fluorescein-labeled Dolichos 353 
Biflorus Agglutinin, DAPI, and BAG1. Disks were removed, mounted on glass slides, and 354 
visualized using microscopy (Nikon Tl7). Slides were scanned using a CRi Panoramic Scan Whole 355 
Slide Scanner and viewed using Panoramic Viewer Software. Effects of compounds were 356 
quantitated by counting cysts in controls and treated cultures. Dolichos staining delimited 357 
structures and  single organisms that remained  were counted in a representative field of view. This 358 
was then multiplied by a factor determined by the total area of the cover slip in order to estimate 359 
the number of cysts and organisms in each condition. When the following forms were observed: 360 
“true cysts” with a dolichos-staining wall, “pseudocysts” or tight clusters of parasites, and small 361 
organisms, if there were fewer than four parasites visible in a cluster, organisms were counted 362 
individually (as “small organisms”). The entire scanned coveslip with all fields was also reviewed 363 
by 3 observers to confirm consistency. 364 
 365 
 366 
Synergy studies with RH strain YFP Tachyzoites.  367 
Atovaquone and pyrimethamine were used to test whether they are synergistic with JAG21. Serial 368 
dilutions of the combination of JAG21 and either atovaquone or pyrimethamine were used in an 369 
in vitro challenge assay as described above. The EC50 of each compound and the combination of 370 
two compounds were determined. The effect of the combination of drugs was calculated with the 371 
following formula:C= [A]c/[A]a+[B]c/[B]a. If C is lower than 1, the two compounds tested have 372 
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synergistic effect; if C is greater than 1, the two compounds tested have antagonist effect and if C 373 
is 1 they are additive.  374 
 375 
T.gondii and HFF Mitochondrial Membrane Potential Measurements—The mitochondrial 376 
membrane potential was measured by the safranine method according to Vercesi et al, 1998). 377 
Freshly egressed T. gondii tachyzoites were filtered and washed twice with intracellular buffer 378 
(125 mM sucrose, 65 mM KCl, 10 mM HEPES-KOH buffer, pH 7.2, 1 mM MgCl2 and 2.5 mM 379 
potassium phosphate). After washing, the parasites were resuspended in the same buffer at 109/ml. 380 
An aliquot of 50 µl of this suspension was added to a cuvette containing Safranin O, 2.5 µM and 381 
Succinate 1 mM in final volume of 2 mL of the intracellular buffer. The fluorescence was measured 382 
with a Hitachi 7000 spectrofluorometer with setting Ex. 495/Em. 586. Once the baseline 383 
fluorescence is testable, 30 µM digitonin was added to permeabilize the parasites.  85 seconds after 384 
permeabilization, the THQ derivatives, dissolved in DMSO, were added. 5 µM of FCCP (Carbonyl 385 
cyanide-4-(trifluoromethoxy) phenylhydrazone) was used as an uncoupler reference for 386 
calculations and its effect was considered 100%. We used similar conditions for measuring the 387 
mitochondrial potential of mammalian cells with the following changes: The mammalian cells 388 
were resuspended at 108/ml. We also used 50 µl of mammalian cells for each run in a cuvette with 389 
2 µl solutions. The substrate used for mammalian cells was 5 mM glutamate and 5 mM malate. A 390 
higher concentration of digitonin (50 µM) was used to permeabilize the mammalian cells. The 391 
compounds were added at ~400 seconds after permeabilization. Each experiment was repeated at 392 
least three times in duplicates. Statistical analysis, unpaired student t test, was performed using 393 
GraphPad Prism 8.0 (GraphPad Software, Inc., San Diego, CA). 394 
Structure Activity Relationship (SAR) and comparison of effect on T.gondii and HFF enzyme 395 
activity.The effects of  changing R1 as 7-Et, 7-Me, 6-CF3, or 6-Me  on activity against RH strain 396 
tachyzoites. kinetic solubility, and metabolic stability were compared. Kinetic solubility and 397 
metabolic stability in human or murine liver microsomes were measured. The hERG ( human 398 
Ether-à-go-go-Related) liability was also determined. The hERG gene (KCNH2) encodes a protein 399 
Kv11.1, the alpha subunit of a potassium ion channel. This channel conducts the rapid component 400 
of the delayed rectifier potassium current, IKr, which is critical for repolarization of cardiac action 401 
potentials. A reduction in hERG currents from adverse drug effects can lead to long QT interval 402 
syndromes. These syndromes are characterized by action potential prolongation, lengthening of 403 
the QT interval on surface EKG, and an increased risk for "torsade de pointes" arrhythmias and 404 
sudden death. The MDCK-MDR1 Permeability Assay was also performed. MDCK-MDR1 refers 405 
to the ability of a compound to permeate across membranes of MDCK-MDR1 (Madin Darby 406 
canine kidney [MDCK] cells with the MDR1 gene [ABCB1], the gene encoding for the efflux 407 
protein, P-glycoprotein (P-gp)) in vitro. Assessing transport in both directions (apical to 408 
basolateral and basolateral to apical across the cell monolayers enables an efflux ratio to be 409 
determined. This provides an indication as to whether a compound undergoes active efflux 410 
(mediated by P-gp). This provides a prediction of blood brain barrier (BBB) penetration 411 
potential/permeability and efflux ratio. Effect in CACO-2 (Colon Adenocarcinoma cells) as a 412 
permeability assay and on cytochrome P450 CYP 450 were also determined. CYP	 enzymes	413 catalyze	 oxidative	 biotransformation	 (phase	1	metabolism)	 of	most	 drugs. CYP	 enzymes,	414 bind	to	membranes	in	a	cell	(cyto)	and	contain	a	heme	pigment	(chrome	and	P)	that	absorbs	415 light	at	a	wavelength	of	450	nm	when	exposed	to	carbon	monoxide.	Metabolism	of	a	drug	by	416 
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CYP	enzymes	is	a	major	source	of	variability	in	drug	effect.	These were measured by Chem 417 
Partners.   The relative effect on HFF and parasite enzymes also were compared.                       .  418 
 419 
RPS13Δ Tachyzoites in Human Primary Brain Neuronal Stem Cells in vitro for 420 
transcriptomics and transcriptomics analyses 421 
Culture of Human Primary Brain Neuronal Stem Cells (NSC) was as described (McPhillie et al, 422 
2016; Ngo et al, 2017); T.gondii RPS13Δ on RH strain background (Hutson et al, 2010) was used 423 
to infect the NSC as described (McPhillie et al, 2016; Ngo et al, 2017). RNA was isolated and 424 
prepared and used for transcriptomic experiments as dervribed (McPhillie et al, 2016; Ngo et al, 425 
2017).Briefly, NSC, initially isolated from a temporal lobe biopsy (Walton et a, 2006) were 426 
infected with either wild-type or RPS13D RH tachyzoites using biological duplicates at a 427 
multiplicity of infection of 2:1  and incubated as previously described (Ngo et al, 2017). Eighteen 428 
hours post-infection, extracellular parasites were washed out with cold PBS before total RNA 429 
extraction. Further isolation of the mRNA fraction was carried out with miRNeasy Mini Kit 430 
columns (Qiagen) following manufacturer instructions and Illumina barcoded mRNA sequencing 431 
libraries were constructed with TruSeq RNA Sample Preparation Kits v2 (Illumina). Libraries 432 
were sequenced as 100 bp single reads with Illumina HiSeq 2000 apparatus at a sequencing depth 433 
of ~3 Gbp per sample. Sequencing reads were mapped to the human (release GRCh38) and T. 434 
gondii ME49 strain (ToxoDB release 13.0) reference genome assemblies with hisat2 (Kim et 435 
al,2015) and raw read counts were per gene were estimated with HTSeq (Anders et al, 436 
2015).  Identification of parasite genes that were differentially expressed between wild-type 437 
and RPS13D  parasites was performed with the R package DESeq2 (Love et al, 2014) using a 438 
generalized linear model likelihood ratio test. Identification of orthologous genes between T. 439 
gondii and P. cynomolgi was carried out by best-reciprocal matches between T. gondii and P. 440 
cynomolgi proteomes using Blastp and a e-value cutoff of 1 x 10-3. The list of Genes that are 441 
differentially expressed between P. cynomolgi hypnozoites and the liver-schizont stage was 442 
extracted from a previously published study by Cubi R. et al (Cubi et al, 2017l). Gene set 443 
enrichment analysis was carried out with the GSEA tool (Subramanian et al, 2005) using T. 444 
gondii Gene Ontology and cell cycle gene sets developed by Croken M et al (Croken et al, 2014l) 445 
and visualized with the Enrichment Map application in Cytoscape (Su et al,2014). 446 
 447 
 448 
T.gondii in vivo 449 
Type II parasites in vivo 450 
IVIS. Balb/C mice were infected intraperitoneally (IP) with 20x103 T.  gondii (Prugneaud strain 451 
expressing luciferase) tachyzoites. Treatment began 2 hours later with JAG21 (5mg/kg) which was 452 
dissolved in DMSO, administered IP in a total volume of 0.05ml. Mice were imaged every second 453 
day starting on day 4 post infection using an IVIS Spectrum (Caliper Life Sciences) for minute 454 
exposures, with medium binning, 20 minutes post injection with 150 mg/kg of D-luciferin 455 
potassium salt solution.   456 
Brain cysts:  457 
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Brain cysts were searched for in paraffin imbedded tissue of the surviving Prugneaud strain 458 
infected treated Balb/C mice in the IVIS study, 30 days after infection which was 16 days after 459 
treatment had been discontinued.  All treated mice had survived. There were no surviving untreated 460 
mice in those experiments.  461 
 462 
In separate experiments, Balb/C mice were infected IP with 20 x 103 T. gondii Me49 strain 463 
tachyzoites.. In these separate studies of mice with established chronic infection, after 30 days, IP 464 
treatment with JAG21 was begun each day for 14 days. JAG21 was dissolved in DMSO and 465 
administered IP in a total volume of 0.05ml. In experiments when tafenoquine was administered 466 
alone or with JAG21 in some groups 3mg/kg tafenoquine was administered once on day -1 from 467 
when JAG21 treatment was initiated. Cysts in brain were quantitated on day 30, 16 days after 468 
discontinuing JAG21. Immunoperoxidase staining was performed. Parasite burden was 469 
quantitated in two ways. The first was using a positive pixel count algorithm of Aperio ImageScope 470 
software. Positive pixels were normalized to tissue area (mm2). Briefly, automated quantitation 471 
was done by counting positive pixels per square area.  The entire brain in one section was scanned 472 
for each mouse.   The Cyst burden was quantitated as units of positive pixels per 473 
mm2.  The average +/- S.E.M. numbers of mm2 per slide quantitated was 30.2+/-1.6 square mm 474 
per mouse for this quantification.   Each highpower field of view shown in Fig.5C is 475 
approximately 0.02 mm^2 per field of view. Cysts on each slide for each condition in two 476 
biological replicate experiments were also quantitated by 2 separate observers independently and 477 
results compared with automated counting, separately. 478 
 479 
RPS13 D in vivo  480 
 481 
This G1 arrested parasite persists in tissue culture for prolonged times in the absence of tetracycline 482 
(Hutson et al 2010), but in immune competent mice it cannot be rescued with teteracycline, or 483 
LNAME ( L-NG-Nitro arginine methyl ester, an analog of arginine) used as an antagonist of nitric 484 
oxide synthase (NOS) that inhibits NO production, or both together (Hutson et al 2010). 485 
  486 
In pilot studies, herein, interferon g receptor knockout mice that were not treated were observed 487 
following infection.  At 7 and at 14 days following infection, spleen and liver were removed and 488 
immune peroxidase stained. At 14 days a group of mice were treated with anhydrotetracycline and 489 
when a subset of these mice died their spleen and liver were removed and immune peroxidase 490 
stained.  491 
As in the pilot studies, this RPS13 D parasite also was used to infect interferon g receptor knockout 492 
mice in a treatment study. The design of this experiment with these immune compromised mice is 493 
shown in Fig. 6. In this separate study, groups of mice were infected with RPS13 D. They were 494 
treated with tafenoquine on day -1, or JAG21 for 14 days 2 hours after infection, or the two together 495 
with tafenoquine on day -1 and JAG21 for the first 14 days, or with diluent only for 14 days, as 496 
described above.  For the initial 14 days no tetracycline was administered. After that time 497 
tetracycline was administered. Mice were observed each day. At the time they appeared to have 498 
substantial illness or at the termination of the experiment they were euthanized, tissues fixed in 499 
formalin and stained with hematoxylin and eosin or immunoperoxidase stained and parasite burden 500 
was assessed. 501 
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RH challenge in a study of oral administration of a novel nano formulation of JAG21.:  502 
Nanoformulation of JAG21 for oral administration in T.gondii studies. JAG21 was prepared 503 
using hydroxyethyl cellulose (HEC) and Tween 80. Briefly, this dispersant solution containing 504 
5mg/mL HEC and 2mg/mL Tween 80 in water was prepared. Solid JAG21 was added to 505 
20mg/mL, and the dispersion was sonicated for 60 seconds using a Sonics vc50 probe-tip sonicator 506 
set to 20kHz to homogenize. Sonication was performed at room temperature. Aliquots of the 507 
homogeneous dispersion were frozen and lyophilized using a VirTis AdVantage freeze drier. 508 
These aliquots were stored at room temperature for 5-6 months. Prior to dosing, aliquots were 509 
reconstituted using water. Controls containing no JAG21 were also prepared. Following 510 
reconstitution with water, the dispersion was imaged using a Nikon ECLIPSE E200 optical 511 
microscope set to 40x magnification. The average particle size of the JAG21 dispersion in 512 
HEC/Tween 80 was determined using an in-house image analysis program  This  novel method to 513 
stably formulate JAG21 was discovered after all other studies were completed and this was the last 514 
experiment in this manuscript performed as a consequence.  515 
RH YFP challenge. For studies of the nano formulated JAG 21, this was administered for one or 516 
three days by gavage in the doses shown in the results section. These C57BL6 background mice 517 
received 2000 RH tachyzoites IP. on day the first day of the experiment and peritoneal fluid was 518 
collected 5 days later to quantitate flluorescence and numbers of parasites. 519 
Malaria assays 520 
 521 
Enzyme assays:  522 
 523 
Methods for enzyme assays:   524 
Materials 525 
P. falciparum 3D7 strain were obtained from the Liverpool School of Tropical Medicine. Protease 526 
cocktail inhibitor was obtained from Roche. Bradford protein assay dye reagent was obtained from 527 
Bio-Rad. All other reagents were obtained from Sigma-Aldrich. Decylubiquinol was produced as 528 
per Fisher et al.(2009). In brief, 25 mg of decylubiquinone were dissolved in 400 µl of nitrogen-529 
saturated hexane. An equal volume of aqueous 1 M sodium dithionite was added, and the mixture 530 
vortexed until colorless. The organic phase containing the decylubiquinol was collected, the 531 
solvent was evaporated under N2 and the decylubiquinol finally dissolved in 100 µl of 96% ethanol 532 
(acidified with 10 mM HCl). Concentrations of decylubiquinol was determined 533 
spectrophotometrically on a Cary 300 Bio UV/visible spectrophotometer (Varian, UK) from 534 
absolute spectra, using ε288 - 320 = 8.1 mM-1 .cm-1. Decylubiquinol was stored at -80 °C and used 535 
within two weeks. 536 
 537 
P.  falciparum culture and extract preparation 538 
P. falciparum strain 3D7 blood-stage cultures were maintained by the method of Trager and Jensen 539 
(1976). Cultures contained a 2% suspension of O+ human erythrocytes in RPMI 1640 medium 540 
containing L-glutamine and sodium carbonate, and supplemented with 10% pooled human AB+ 541 
serum, 25 mM HEPES (pH 7.4) and 20 µM gentamicin sulphate. Cultures were grown under a 542 
gaseous headspace of 4 % O2 and 3% CO2 in N2 at 37°C. Cultures were grown to a parasitemia of 543 
5 % before use. 544 
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 545 
The protocol for the preparation of parasite extract was adapted from Fisher et al.30. Free parasites 546 
were prepared from infected erythrocytes pooled from five T75 flasks, by adding 5 volumes of 547 
0.15% (w/v) saponin in phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 1.76 mM 548 
K2HPO4, 8.0 mM Na2HPO4, 5.5 mM D-glucose, pH 7.4) for 5 min, followed by three washes by 549 
centrifugation in RPMI containing HEPES (25 mM), and a final resuspension in potassium 550 
phosphate buffer (50 mM K2HPO4, 50 mM KH2PO4, 2 mM EDTA, pH7.4) containing a protease 551 
inhibitor cocktail (Complete Mini; Roche). Parasite extract was then prepared by disruption with 552 
a sonicating probe for 5 s, followed by a 1 min rest period on ice to prevent the sample overheating. 553 
This process was performed three times.  The parasite extract was used immediately. The protein 554 
concentration of the parasite extract was determined by Bradford protein assay (Bio-Rad). 555 
 556 
Pfbc1 native assay 557 
P. falciparum bc1 complex cytochrome c reductase (Pfbc1) activity was measured by monitoring 558 
cytochrome c reduction at 550 versus 542 nm using a Cary 300 Bio UV-Visible Spectrophotometer 559 
(Varian, UK), using a protocol adapted from Fisher et al. (2009).The assay was performed in 560 
potassium phosphate buffer in a quartz cuvette and in a final volume of 700 µL. Potassium cyanide 561 
(10 µM), oxidized cytochrome c (30 µM), parasite extract (100 µg protein) and compound/DMSO 562 
were added sequentially to the cuvette, with mixing between each addition. Test compounds were 563 
added to a final concentration of 1 µM. DMSO (0.1% v/v) and atovaquone (1 µM), a known 564 
malarial cytochrome bc1 complex inhibitor, were used as negative and positive controls 565 
respectively. The reaction was initiated by the addition of 50 µM decylubiquinol and allowed to 566 
proceed for 3 min.  567 
 568 
Malaria parasite In vitro studies: 569 
Malaria potency testing in vitro was performed using 4 different P.  falciparum strains, D6, TM91-570 
C235, W2, and C2B. The D6 strain is a drug sensitive strain from Sierra Leone, the TM91-C235 571 
strain is a multi-drug resistant strain from Thailand, the W2 strain is a chloroquine resistant strain 572 
from Thailand, and the C2B strain is a multi-drug resistant strain with resistance against 573 
atovaquone. These assays were performed as described below.  574 
 575 
Compound Activity against Plasmodium falciparum 576 
Compound activity against P. falciparum, was tested using the Malaria SYBR Green I - Based 577 
Fluorescence (MSF) Assay. The complete method for performing this microtiter assay is described 578 
in previous work published by Plouffe et al.(2008) and Johnson et al (2007). In brief, this assay 579 
uses the binding of the fluorescent dye SYBR Green I to malaria DNA to measure parasite growth 580 
in the presence of two-fold diluted experimental or control. The relative fluorescence of the 581 
intercalated SYBR Green I proportional to parasite growth, and inhibitory compounds will result 582 
in lower observed fluorescence compared to untreated parasites. 583 
 584 
Cytotoxicity assays in parallel with  P.falcipaum assays in vitro   585 
Toxicity studies also were performed with HepG2 cells (human liver cancer immortal cell line 586 
derived from the liver tissue of a 15-year-old African American, ATCC R HB-8065TM )  in 587 
parallel with the studies of P.falciparum,  with inhibitors in vitro , as described in McPhillie et al 588 
(2016). 589 
 590 
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 P. berghei causal prophylaxis in vivo model 591 
P. berghei sporozoites were obtained from laboratory-reared female Anopheles stephensi 592 
mosquitoes which were maintained at 18 degrees C for 17-22 days after feeding on a luciferase 593 
expressing P. berghei infected Swiss CD1ICR Using a dissecting microscope, the salivary glands 594 
were extracted from malaria-infected mosquitoes and sporozoites were obtained. Briefly, 595 
mosquitoes were separated into head/thorax and abdomen. Thoraxes and heads were triturated 596 
with a mortar and pestle and suspended in medium RPMI 1640 containing 1% C57BL/6 mouse 597 
serum (Rockland Co, Gilbertsville, PA, USA). 50–80 heads with salivary glands were placed into 598 
a 0.5 ml Osaki tube on top of glass wool with enough dissection media to cover the heads. Until 599 
all mosquitoes had been dissected, the Osaki tube was kept on ice. Sporozoites that were isolated 600 
from the same batch of mosquitoes were inoculated into C57BL/6, 2D knock-out and 2D knock-601 
out/2D6 knock-in C57BL/6 mice on the same day to control for biological variability in sporozoite 602 
preparations. On day 0, each mouse was inoculated intravenously in the tail vein with 603 
approximately 10,000 sporozoites suspended in 0.1 ml volume. They were stained with a vital dye 604 
containing fluorescein diacetate (50 mg/ml in acetone) and ethidium bromide (20 µg/ml in 605 
phosphate buffered saline; Sigma Chemical Co, St. Louis, MO, USA) and counted in a 606 
hemocytometer to ensure that inoculated sporozoites were viable following the isolation 607 
procedure. Viability of the sporozoites ranged from 90 to 100%. 608 
 609 
Animals 610 
The mice  used in these experiments were albino C57BL/6 female mice which were housed  in 611 
accordance with the current Guide for the Care and Use of Laboratory Animals (1996) under an 612 
IACUC approved protocol. All animals were quarantined for 7 days upon arrival, and the animals 613 
were fed standard rodent maintenance food throughout the study. 614 
 615 
Test compounds, homogenization of JAG21 creating a nanoformulation, and administration 616 
Animals were dosed with experimental compounds based on body weight. The suspension solution 617 
of orally administered drugs were conducted in 0.5% (w/v) hydroxyethyl cellulose and 0.2% 618 
Tween 80 in distilled water. To insure the size of the compounds in the dosing solution were under 619 
50 µM (measured they were  4-6 µ), the suspension was homogenized using a homogenizer (PRO 620 
Scientific Inc, Monroe, CT, USA) with a 10 mm open-slotted generator running at 20,000-22,000 621 
rpm for 5 min in an ice bath. The compounds were made fresh each day and used immediately 622 
(always in <1/2 hour). Stability beyond that time was not determined. It was not anticipated that 623 
they would be stable beyond that time.  624 
 625 
Compounds were administered on 3 consecutive days (−1, 0, +1) relative to sporozoite infection 626 
or a single dose on day 0. Drug suspensions were administered to mice by oral gavage using an 18 627 
gauge intragastric feeder.  For the 3 day dosing regimen, compounds were administered at 0.625 628 
mg/kg and for the single dose regimen administered on day 0, compounds were administered at 629 
2.5 mg/kg. 630 
 631 
In vivo imaging  632 
All of the in vivo bioluminescent imaging methods utilized have been described previously. 633 
Briefly, JAG21 was  administered orally on days −1, 0 and 1 with respect to sporozoite inoculation. 634 
All inoculated mice were imaged using the Xenogen IVIS-200 Spectrum (Caliper Life Sciences, 635 
Hopkinton, MA, USA) IVIS instrument at 24, 48 and 72 hours post-sporozoite infection. The 636 
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bioluminescent imaging experiments were conducted by IP injection of the luciferase substrate, 637 
D-Luciferin potassium salt, (Xenogen, California and Goldbio, St Louis, MO, USA), into mice at 638 
a concentration of 200 mg/kg 15 min before bioluminescent images were obtained. Three minutes 639 
after luciferin administration the mice were anesthetized using isoflurane, and the mice were 640 
positioned ventral side up on a 37degree C platform with continual anesthesia provided through 641 
nose cone delivery of isoflurane. All bioluminescent images were obtained using 5minute 642 
exposures with f-stop = 1 and large binning setting. Photon emission from specific regions was 643 
quantified using Living Image® 3.0 software (Perkin Elmer),  644 
 645 
Additionally, blood stage parasitemia was assessed 3 days after imaging was completed by treating 646 
small quantities of blood obtained from tail bleeds with  the fluorescent dye Yoyo-1 measured by 647 
using a flow cytometry system (FC500 MPL, Beckman Coulter, Miami, FL, USA), (Pybus et al, 648 
2013; Marcissin et al, 2014) 649 
 650 
 651 
Methods for Co-Crystallization and binding studies  652 
Bovine cytochrome bc1 activity assays. 653 
Bovine cytochrome bc1 inhibition assay was carried out in 50mM KPi pH 7.5, 2 mM EDTA, 654 
10mM KCN, 30µM equine heart cytochrome c (Sigma Aldrich), and 2.5 nM bovine cytochrome 655 
bc1 at room temperature. 20 mM inhibitors dissolved in DMSO were added to the assay at a desired 656 
concentration without prior incubation. The working concentration of DMSO in the assay did not 657 
exceed 0.3% v/v. The reaction was initiated by the addition of 50 µM decylubiquinol (Abcam). 658 
The reduced cytochrome c was monitored by the different absorption between 550 and 542 nm 659 
using extinction coefficient of 18.1 mM-1cm-1 in a SPECTRAmax Plus 384 UV-visible 660 
Spectrometer. The initial kinetic rate is determined as a zero-order reaction and used as the specific 661 
activity of cytochrome bc1. 662 
Bovine Cytochrome bc1 purification protocol: 663 
Preparation of crude mitochondria  664 
Whole fresh bovine heart was collected after slaughter and transported in ice.  All work was carried 665 
out at 4 °C.  Lean heart muscle was cut into small cubes and homogenized in the buffer composed 666 
from 250 mM sucrose; 20 mM K2HPO4; 2 mM succinic acid; 0.5 mM EDTA. Buffer was added 667 
at a ratio of 2.5L per 1 kg of muscle tissue. Ph of resulting homogenate was adjusted to 7.8 using 668 
2 M Tris and PMSF protease inhibitor was added to 0.1 mM concentration.  The homogenate was 669 
then centrifuged in a Sorvall GS-3 rotor at 5000g for 20 mins.  The resulting supernatant was then 670 
transferred to a Sorvall GSA rotor and centrifuged at 20,000g for 20 mins.  Obtained mitochondrial 671 
pellet was washed in 50 mM KPi (pH 7.5); 0.1 mM PMSF buffer before second centrifugation 672 
under the same condition.  The pellet was collected and sored at -80 °C for further use. 673 
Solubilisation of membrane proteins 674 
The frozen mitochondria were thawed and re-suspended in 50 mM KPi (pH 7.5); 250 mM NaCl; 675 
0.5mM EDTA; 0.1 mM PMSF buffer; a small sample was taken for quantification of total 676 
mitochondrial proteins by BCA assay.  The remaining sample was centrifuged at 180,000g in 677 
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Beckman Ti70 rotor for 60 mins.  The pellet was re-suspended in the same wash buffer with the 678 
addition 1 mg DDM per 1 mg of protein and then centrifuged under the same conditions for 60 679 
mins.  The pellet was discarded and the supernatant was collected for ion exchange 680 
chromatography. 681 
Purification of cytochrome bc1  682 
During purification the presence of protein was detected using 280 nm absorbance and the presence 683 
of heme was detected using 415 nm Soret band peak and 562 nm absorbance.  The solubilized 684 
protein solution was applied on DEAE-Sepharose CL-6B column (ca. 50 ml, GE Healthcare) pre-685 
equilibrated with buffer A (50 mM KPi (pH 7.5); 250 mM NaCl; 0.01 % w/v DDM; 0.5mM 686 
EDTA) and washed with 3 CV of buffer A. The protein was eluted by linear gradient with buffer 687 
B (50 mM KPi (pH 7.5); 500 mM NaCl; 0.01%w/v DDM; 0.5mM EDTA). Fractions containing 688 
cytochrome bc1 were pooled and concentrated to 0.5 ml using an Amicon Ultra-15 (Amicon, 689 
MWCO 100,000) concentrator. Concentrated sample was applied to a Sephacryl-S300 gel 690 
filtration column (ca. 120 ml) pre-equilibrated in buffer C (20 mM KMOPS (pH 7.2); 100 mM 691 
NaCl; 0.01%w/v DDM; 0.5 mM EDTA) and eluted at a flow rate of 0.5 ml/min.  Purified 692 
cytochrome bc1 fractions were collected and concentrated to 40 mg/m. PEG fractionation with 693 
increasing concentration of PEG4000 was used to precipitate cytochrome bc1. Precipitating 694 
solution (100 mM KMES pH 6.4; 10% PEG4000; 0.5 mM EDTA) was mixed with the protein to 695 
a desired PEG concentration. The precipitated protein pellet was re-solubilised in buffer D (25 696 
mM KPi pH 7.5, 100 mM NaCl, 0.5 mM EDTA, 0.015% DDM) and dialysed in the same buffer 697 
in a centrifugal ultrafilter to remove residual PEG. 5 µM cytochrome bc1 was incubated at 4 oC for 698 
12 hours with 50 µM JAC021 (10-fold molar excess) diluted from 20mM solution stock in DMSO. 699 
 700 
Crystallization, data collection and refinement of Cytochrome bc1 - JAG021 complex 701 
 702 
The inhibitor-bound cytochrome bc1 was mixed with 1.6% HECAMEG to the final protein 703 
concentration of 40 mg/mL. Hanging drop methods was used for crystallisation. 2 µL of final 704 
protein solution with 2 µL of reservoir solution (50 mM KPi pH 6.8, 100 mM NaCl, 3 mM NaN3, 705 
10-12% PEG4000) was equilibrated over reservoir solution at 4 oC. The crystals were grown to 706 
100 µm within four days. The single crystal was transferred in reservoir solution containing 707 
increasing to 50% concentrations of ethylene glycol prior to cryo-cooling in liquid nitrogen. X-ray 708 
data were collected from single crystal PROXIMA2 beamline, SOLEIL light source, France using 709 
DECTRIS EIGER X 9M detector at 0.9801Å wavelength up to 3.45Å resolution. Data were 710 
indexed and integrated using iMosflm (Battye et al, 2011), and scaled using Aimless (Evans, 711 
2011). The starting model for refinement was 5OKD. All ligands except co-factors were removed 712 
from the model prior to refinement. Jelly-body refinement was carried out with Refmac5 713 
(Murshudov et al, 2011). The inhibitor model was generated by Jligand (Lebedev et al, 2012). The 714 
model was manually edited in COOT (between cycle refinements. Data collection and refinement 715 
statistics are shown in Supplemental Table S1). 716 
 717 
 718 
Co-cryo electron microscopy 719 
Electron microscopy and image processing 720 
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Cryo-EM was carried out as described in Amporndanai et al. (2018).  Briefly, 3 µL of sample at 5 721 
mg/mL concentration were applied to Quantifoil Cu R1.2/1.3, 300 mesh holey carbon grids and 722 
plunge frozen using an FEI Vitribot (blot time 6 seconds, blot force 6). Data were collected on an 723 
FEI Titan Krios with a Falcon III direct electron detector operated in integrating mode at 300 kV. 724 
Automated data collection was carried out using EPU software with a defocus range of -1 to -3.5 725 
µm, and a magnification of 75,000 x which yielded a pixel size of 1.065 Å. Data were collected 726 
for 72 hours resulting in 5,356 micrographs. The total dose was 66.4 e-/Å over a 1.5 second 727 
exposure which was split into 59 frames. All of the processing was performed in RELION 2.1 728 
unless otherwise stated. The initial drift and CTF correction was carried out using 729 
MOTIONCORR2 (Zheng et al, 2017) and Gctf (Zhang,et al., 2016)  respectively. The micrographs 730 
were examined and those with crystalline ice were initially removed resulting in 2,960 731 
micrographs. A subset of ~2,000 particles were manually picked to generate 2D references to 732 
facilitate auto-picking resulting in 439,009 particles. These particles underwent an initial round of 733 
2D classification with those classes that displayed clear secondary structure detail being taken 734 
forward to 3D classification and split into three classes. Two of the three classes generated a high-735 
quality cytochrome bc1 reconstruction with secondary structure information clearly visible. The 736 
particles from these two classes were recombined to form the final datasets consisting of 211,916 737 
particles in the final reconstruction. The particles were 3D refined using C2 symmetry to produce 738 
a map with resolution 3.8 Å. The particles also underwent movie refinement and particle polishing 739 
which further improved the resolution of the map to 3.7 Å. A previously refined EM structure for 740 
SCR0911 (pdb 6FO6) was fit into the map using UCSF chimera and subsequently refined using 741 
phenix with the correct ligand. The maps were then inspected manually in COOT (Emsley et al 742 
2004) and the model corrected for any errors in refinement and the placement of residues. 743 
 744 
Statistical Analysis 745 
A Pearson test was used to confirm a correlation between increasing dose and increasing inhibition. 746 
An ANOVA and subsequent pairwise comparison with Dunnett correction was used to determine 747 
whether or not inhibition or toxicity at a given concentration was statistically significant. Stata/SE 748 
12.1 was used for this analysis.  749 
 750  751 
 752 
RESULTS 753 
 754 
THQ compounds are potent in vitro 755 
Initially, a small library of seven compounds (Figs. 1 [blue and green font, Fig. 1A] and 2) were 756 
tested, and each compound was tested at least twice against T. gondii tachyzoites. JAG021 and 757 
JAG050 demonstrated effect below 1 µM, and were tested at lower concentrations. JAG050 and 758 
JAG021 were identified as lead compounds given the IC50 values obtained were 33 and 55 nM, 759 
respectively. Correlation between concentration of compound and inhibition of parasite replication  760 
(as measured by fluorescence) was observed for all compounds except JAG046. The relative effect 761 
on HFF and parasite enzymes were also compared, with those marked ** in Fig. 1A having the 762 
most effect on the parasite enzyme activity relative to host HFF enzyme activity as shown below 763 
in Fig 3.   764 
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A representative graph of these in vitro data is shown in Fig. 2A. Subsequently, a larger library of 765 
54 compounds was synthesized to ascertain structure-activity relationships (SAR) (Fig. 1B). Our 766 
primary aims were to block putative metabolism of the terminal phenol ring of MJM170 and 767 
improve the solubility across the compound series. Substituents were generally tolerated at the 768 
meta and para positions on the phenol ring (R1), similar to the trends observed in the ELQ series 769 
(McPhillie et al, 2016; Dogget et al 2012, Vidigal et al 2002). The incorporation of heteroatoms 770 
into the aryl rings of the biphenyl moiety did not lead to improvements in solubility and biological 771 
activity. Small substituents were tolerated at the 7-position of the THQ bicyclic ring (Fig. 1B; R1), 772 
improving selectivity (see below, SAR) but not at the 6-position unlike the ELQ series. In 773 
summary, overall, nitrogen atoms not tolerated in aryl ring (C) and the 4-position was optimal for 774 
phenol substituent. Ultimately, no other compound had all the advantages of JAG21, although 775 
some of these were identified as potential back up compounds(marked with **), with greater 776 
selectivity for the parasite relative to the mammalian enzyme activity. Compound JAG21 777 
displayed synergy against RH strain tachyzoites with atovaquone (Fig. 2C) but not with 778 
pyrimethamine, although no antagonism was observed (data not shown).	 779 
 780 
Cytotoxicity assays performed in parallel using HFF, WST-1 (Fomovska et al,  2012; Fomovska, 781 
et al 2012a) , and HEP G2 cells demonstrated a lack of toxicity at concentrations substantially in 782 
excess of the concentrations effective against tachyzoites. Because T. gondii grows inside cells, if 783 
a compound were toxic to host HFF then it would make the compound appear to be spuriously 784 
effective (Fomovska et al,  2012; Fomovska, et al 2012a), when in actuality only toxicity for the 785 
host cell would be measured. Cytotoxicity to HFF was therefore assessed for all compounds at 10 786 
µM. Results of this experiment are in Fig. 1A, toxicity column. A two-way ANOVA and 787 
subsequent pairwise comparison found none of the differences in absorbance, compared to the 788 
media-DMSO vehicle controls, to be statistically significant (p>0.05). Most of these compounds 789 
are not toxic at 10µM (the limit of solubility) and that cytotoxicity to cells can be attributed to 790 
DMSO in the solution, not the compound. Dose response testing (IC50) was performed with HEP 791 
G2 cells as described and the observed toxicity was: HEP G2 IC50 17.70 µM (r2= 0.97) for 792 
JAG021; 7.1 µM (r2= .98) for JAG050. 793 
 794 
       Lead compounds JAG050, JAG021 and others were tested against EGS strain(McPhillie et al, 795 
2016; Vidigal et al, 2015; Paredes-Santos et al 2013; Paredes-Santos et al,2018) tachyzoites and 796 
encysted bradyzoites using methods described earlier (McPhillie et al, 2016) . We found a number 797 
of these compounds including JAG21 were highly effective against tachyzoites (RH-YFP; 798 
Fomovska et al, 2012) (Figs. 1A, 2A,C) and bradyzoites of  EGS (McPhillie et al, 2016; Vidigal 799 
et al, 2015; Paredes-Santos et al 2013; Paredes-Santos et al,2018) (Fig 2B). For example, in a 800 
separate experiment (data not shown) using immunofluorescence microscopy, the following forms 801 
were observed: “true cysts” with a dolichos-staining wall, “pseudocysts” or tight clusters of 802 
parasites, and small organisms. If there were fewer than four parasites visible in a cluster, 803 
organisms were counted individually (as “small organisms”). A statistically significant reduction 804 
in the number of true cysts and small organisms was observed at 1 µM and 10 µM for both 805 
compounds (p <0.05, p<0.005). 500nM JAG21 treatment results in cultures where we do not see 806 
EGS bradyzoites (e.g., Fig. 2B).  807 
 808 
Results against P. falciparum using methodology described earlier (McPhillie et al, 2016,Trager 809 
et al, 2005, Ploufe et al,2008, Johnson et al, 2007 ) also are shown in Fig. 2D. JAG 21 is potent 810 
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against P. falciparum with IC50 values ranging from 14-61 nM against a variety of drug sensitive 811 
and resistant strains (McPhillie et al 2016) including D6, TM91-C235, W2, and C2B. The D6 812 
strain is a drug sensitive strain from Sierra Leone, the TM91-C235 strain is a multi-drug resistant 813 
strain from Thailand, the W2 strain is a chloroquine resistant strain from Thailand, and the C2B 814 
strain is a multi-drug resistant strain resistant to atovaquone. Effects of other comparison 815 
compounds are also shown in this table and range from 31 to 20,000 nM (Fig. 2D). 816  817 
ADMET superiority of JAG21 818 
 In vitro absorption, distribution, metabolism, excretion, and toxicity (ADMET) analyses of the 819 
THQ compounds were outsourced to ChemPartner Shanghai Ltd. ELQ-271 (synthesized in-house) 820 
was tested as a comparison.  THQs which were potent inhibitors of T. gondii tachyzoites were 821 
assessed for their kinetic solubility, metabolic stability in human and mouse liver microsomes (Fig. 822 
2E), hERG, and their ability to permeate across MDCK-MDR1 cell membranes (in vitro measure 823 
of blood-brain barrier (BBB) penetration potential/permeability). Solubility, half-life, HERG, and 824 
BBB permeability/efflux results are shown in Fig. 2F. The aqueous solubility (PBS, pH 7.4) of 825 
amorphous compounds JAG021 and JAG050 was 7 and 16 µM respectively, which is improved 826 
over MJM170 (2 µM) and ELQ-271 (0.2 µM). We also tested solubility of the microcrystalline 827 
form of JAG21 and found that the solubility was 3.5 µM.  JAG021 was the most metabolically 828 
stable compound in human liver microsomes (>99% remaining after 45 mins) compared with other 829 
THQs and ELQ-271, although it displayed a much shorter half-life of 101 mins in mouse liver 830 
microsomes. All THQs tested in the MDCK-MDR1 system for blood brain barrier (BBB) 831 
permeability (including MJM170, JAG021 and JAG050), exhibited high permeability (Papp >10 x 832 
106 cm/s) and low efflux (efflux ratio <1.5).   833  834 
THQs potently inhibit parasite Cytochrome bc1 (Cytbc1) enzyme activity 835 
JAG21 is the most active of the initially tested THQs against T. gondii Cytbc1, which also showed 836 
selectivity for the parasite over the mammalian mitochondrial membrane potential (Fig. 3). 837 
Following the full SAR testing in vitro activity against tachyzoites, the full set of compounds was 838 
tested against HFF; then the initial compounds also were tested against the T.gondii and HFF 839 
enzyme benchmarked against atovaquone, and ultimately the full set of compounds was compared 840 
for effect against the T. gondii and HFF enzymes.  841 
 842 
 Mitochondrial membrane potential measurements were performed with permeabilized T.gondii 843 
tachyzoites in suspension using safranin O, which loads into polarized membranes (see Materials 844 
and Methods in the supplemental materials [Vercesi,1998]). T. gondii tachyzoites were 845 
permeabilized with digitonin to allow the mitochondrial substrate succinate to cross the membrane 846 
and energize the mitochondrion. The fluorescence of safranin O, which loads into energized 847 
mitochondria was used to measure the membrane potential. The energized state of the 848 
mitochondrion is observed by a decrease in fluorescence (Figs. 3A, C, E). Trifluoromethoxy 849 
carbonylcyanide phenylhydrazone (FCCP) was used to depolarize the membrane, which causes 850 
the fluorescence to go up as shown in Fig. 3A. JAG21 depolarized the membrane potential even 851 
at concentrations as low as 2 nM (Fig. 3C, D). JAG21 and Atovaquone had similar effects on the 852 
mitochondrial membrane potential (Fig. 3D).. Fig. 3F is host cells so indicates that it is less toxic. 853 
Other compounds like JAG46 and 47 showed almost no effect at doses as high as 4 µM (Fig. 854 
3A,B). JAG50 showed depolarizing activity at doses of 200 nM and higher. The effect of these 855 
THQ compounds against the T. gondii mitochondrial membrane potential was greater than the 856 
effect on the human foreskin fibroblast membrane potential (Fig. 3E,F). This is consistent with 857 
the observation that JAG21 is less toxic against human Telomerase reverse transcriptase 858 
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immortalized  (hTERT) HFF cells than atovaquone. We had newly created THQ compounds, not 859 
yet characterized fully, that show even less toxicity to the human fibroblast cytochrome b/c 860 
complex marked with ** in Fig 1A. These could be developed in a second phase of our program 861 
were reductions in toxicity needed. However, as data presented herein demonstrates, there are 862 
significant advantages in the ADMET properties of JAG 21, and its dramatic efficacy in vivo, 863 
without toxicity. There may be no need to further develop any of those potential additional leads. 864 
 865 
Enzyme reduction of cytochrome c by P. falciparum parasite extract (Fisher et al, 2004, 2009) is 866 
mediated by P. falciparum bc1 complex cytochrome c reductase (Pfbc1) enzyme.  All three 867 
compounds tested (1 µM) significantly inhibited the reduction of cytochrome c by the P. 868 
falciparum parasite extract, (JAG021 = 86.4 ± 3.2; JAG099 = 81.3 ± 6.0; MJM170 = 69.7 ±11.3 869 
% of the atovaquone response, Fig. 3G. Additional data demonstrated selective effect on P. 870 
falciparum enzyme compared with bovine enzyme (data not shown).  871  872 
  873 
  Binding, Co-crystallography, Pharmacophore and Co-Cryo-Electron Microscopy  Studies  874 
Demonstrate Selectivity 875 
  In binding assays and in co-crystallography (McPhillie et al, 2016; Capper et al ,2015; 876 
Amporndanai et al, 2018; Battye et al, 2011; Emsley et al, 2010; Laskowski and Swindells, 877 
2011;Lbebedev et al, 2012; Murshudov et al, 2011; Emsley et al, 2004; Zheng et al, 2017; Zhang 878 
et al, 2016), JAG021 has lower binding affinity to bovine cytochrome bc in comparison with 879 
previous compounds that we have tested. JAG 21 ‘inhibits' Cytbc1 but not fully, indicating that it 880 
will be less toxic for mammalian (bovine/human) cyt bc1 than the apicomplexan enzymes ( Fig. 881 
4A).  The electron density map in the Qi site of bovine cytochrome bc1 complex with JAG021 882 
(Table S1, Data Collection Statistics)) reveals an additional electron density, which allowed 883 
unambiguous positioning of the inhibitor (Fig. 4B). No additional electron density was found 884 
within the Qo site. After the refinement, 2Fo-Fc electron around JAG021 becomes clearer (Fig. 885 
4C). The second aromatic ring in the tail group of the compound is less defined due to high 886 
flexibility introduced by the oxygen linker. The quinolone head of JAG021 is held between 887 
Asp228 and His201 and adapted the same conformation as 4(1H)-pyridone (GSK932121)(Capper 888 
et al, 2015)  (Fig. 4D) and tetrahydro-4(1H)-quinolone (MJM170) (McPhillie et al, 2016)  (Fig. 889 
4E) by directing the NH group to His201 and the carbonyl group to Asp228. The carbonyl of the 890 
quinolone head and OG1 atom of Ser35 are within 3.0 Å distance that allows hydrogen bonding 891 
and enhances the binding affinity to the bovine enzyme. The 3-diarylether tail extends along a 892 
hydrophobic channel defined by Gly38, Ile39 and Ile42. The trifluoromethoxy group at the 893 
phenoxy ring points towards Met190 and Met194 (Fig. 4F). CryoEM studies of the complex also 894 
demonstrates reasons for selectivity. In Fig. 4F, the density suggests that the inhibitor can adopt 895 
two different binding poses as observed previously in the cryo-EM structure of 896 
GSK932121(Capper et al, 2015).  The binding pose shown in yellow, which has the strongest 897 
density, agrees with the crystal structure and has the trifluoromethoxy group pointing towards 898 
Met194. However, there is additional density which could result from a second binding pose 899 
(green) in which the trifluoromethoxy group points towards Asp228(McPhillie, 2016 et al).   Fig. 900 
4F, shows GSK932121 pyridone (PDB:4D6U) (G) MJM170 quinolone (PDB:5NMI). 901  902 
JAG21 is potent in vivo  903 
In vivo studies of JAG21 against T. gondii demonstrated high efficacy in a variety of settings.  904 
JAG21 at 5 mg/kg/day administered IP improves well-being and eliminates illness and T. gondii 905 
Type II Prugneaud  luciferase tachyzoites completely in luminescence studies (Fig. 5A).  Further, 906 
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treatment beginning on day one after infection results in no cysts being found in brains of these 907 
mice treated for 14 days with 5mg/kg/day of JAG21, when brains were evaluated 30 days after 908 
stopping JAG21 treatment in two replicate experiments. Treatment beginning on day 30 after 909 
initiation of infection with Type II Me49 parasites results in marked, statistically significant 910 
reduction in normal appearing cysts, free organisms and immunoperoxidase stained cysts detected 911 
by automated imaging of scanned slides (Figs. 5 B,C, p<0.03 experiment ; p<0.01 experiments 1 912 
and 2 together, Supplemental Fig.S1). The automated analysis confirmed results from the blinded 913 
microscopic visual quantitation of cysts and free organisms in slides by two observers. Adding 914 
tafenoquine or primaquine to treatments of active plus dormant malarias(St.Jean et al, 2016; 915 
Lacerda et al, 2019; Llanos-Cuentas et al 2019) is partially effective against both active and 916 
dormant phase plasmodia, when neither treatment of active nor dormant disease alone is effective 917 
for either in vivo. We developed experiments based on these observations where experiments with 918 
tafenoquine alone or with JAG21 alone was used in the experiments with established cyst with 919 
immune competent mice. This was to determine whether tafenoquine might add to efficacy of 920 
JAG21.  The efficacy of treatment with JAG21 alone was so robust (Fig. 5B), that no additive 921 
effect was seen, or could have been detected, by adding Tafenoquine to JAG21. Efficacy was 922 
shown when data were analyzed as separate groups, i.e., control vs JAG21 alone (p<0.03) or 923 
control vs JAG21 plus tafenoquine, or grouping the JAG21 and JAG21 plus tafenoquine results as 924 
“untreated” versus “treated” (p<0.01). Analysis shown combining both treatment groups from two 925 
replicate experiments  showed similar results (p<0.01).(Fig 5B), and when results from replicate 926 
experiments were grouped(Supplemental Fig S1). In Fig 5C the control mice had cysts with usual 927 
morphology (Top two panels), whereas treated mice had very few morphologically recognizable 928 
usual cysts that were immunostained (bottom panels). 929 
         A nano formulation homogenized (<6 µM) was used effectively  orally for  the P.bergheii 930 
experiments, further, importantly, was effective in the single oral dose causal prophylaxis in 5 931 
C57BL/6 albino mice at 2.5 mg/kg dosed on day 0, 1 hour after intravenous administration of 932 
10,000 P. berghei sporozoites was completely protective. In addition, 3 dose causal prophylaxis 933 
treatment in 5 C57BL/6 albino mice at 0.625 mg/kg dosed on days -1, 0, and +1 also was 934 
completely protective. A representative experiment at a higher dose (5 mg/kg) is shown, but all 935 
experiments with the oral dosing regimen with the nanoformulation specified above showed 100% 936 
survival 30 days post infection with P. berghei, where all liver and blood stage parasites were 937 
eliminated (Fig. 5D,E) demonstrates not only efficacy of JAG21 against the three life cycle stages 938 
of P. berghei, but also demonstrates the efficacy of oral administration of the nanoformulation 939 
when used immediatel, at a low dose. 940   941 
G1 Arrest, Persisters, Companion Compounds 942 
        In mice that were treated with JAG21 early after infection (Fig 5A) we could find no residual 943 
immunostaining for T.gondii in brain tissue of any mice. This suggests that very early treatment 944 
could prevent established, chronic infection, for example in epidemics such as those that occurred 945 
in Victoria, Canada, the U.S.A., and Brazil. In mice with established cysts, following treatment 946 
with JAG21, we occasionally saw a small number of cysts (Fig 5B) and amorphous immunostained 947 
structures (Fig. 5C bottom panels). This was reminiscent of persistence in some malaria infections 948 
(Cubi et al, 2017) and abnormal immunostained structures we previously identified with a 949 
conditional, tetracycline-on regulatable, mutant T.gondii (Hutson et al, 2010 and Fog.S2).  In this 950 
DRPS13 tachyzoite, small ribosomal protein 13 can be regulated, depending on whether 951 
anhydrotetracycline (ATc) is absent or present, leading the ATc responsive repressor to be on or 952 
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off response elements engineered into the promoter (Hutson et al, 2010). DRPS13 replicates with 953 
ATc present and is arrested in G1 when ATc is absent in HFF cultures (Hutson et al 2010). The 954 
dormant parasite could persist for extended periods (Hutson et al, 2010). The parasite could be 955 
rescued from its dormant – ATc state by adding ATc, months after removing tetracycline from 956 
infected HFF cultures, although it could not be rescued in immunocompetent mice with LNAME 957 
and ATc when tested one week after infection (Hutson et al 2010). We wondered if this type of 958 
dormant organism could form in vivo, whether it could contribute in a biologically relevant way 959 
to dormancy and recrudescence, similar to the malaria hypnozoite, and whether JAG 21 might be 960 
able to eliminate it, or whether a companion compound effective against this form might be needed 961 
or work in conjunction with JAG21 if needed. To begin to address these questions and to 962 
investigate how close the T. gondii DRPS13 -ATc phenotype might be to the malaria hypnozoite, 963 
we compared the transcriptome of T. gondii DRPS13 in human, primary, brain, neuronal stem cells 964 
+/-ATc to the recently published P. cynomolgi hypnozoite transcriptome, established with single 965 
cell RNA sequencing in laser captured organisms (Cubi et al, 2017). This analysis identified 28 966 
orthologous genes with similar expression pattern in both T. gondii DRPS13 -ATc and P. 967 
cynomolgi hypnozoites, including the downregulation of rps13 and upregulation of the eukaryotic 968 
initiation factor-2a kinase IF2K-B, a protein involved in translational control in response to stress 969 
(Cubi et al 2017) (Fig 6A). Further. assessment of the T. gondii DRPS13 transcriptome in the 970 
absence or presence of ATc showed upregulation of additional IF2K members, 25 Apetela (AP) 2 971 
transcription factors and a number of genes that participate as protein ubiquitin ligases, and in 972 
trafficking as well as in RNA binding (Supplemental Table S2). None of them, except for 973 
AP2VIIa-7, have been shown to be upregulated nor downregulated during differentiation to 974 
bradyzoites. Gene set enrichment analysis showed that in the absence of ATc, the T. gondii 975 
DRPS13 transcriptome is enriched in genes typically expressed during G1, confirming previous 976 
results indicating that downregulation of rps13 arrests the parasite at this stage of the cell cycle 977 
(Fig. 6B) (Hutson et al, 2010). Moreover, a number of biological processes are downregulated 978 
without ATc, including protein synthesis and degradation as well as energy metabolism (Fig. 6B). 979 
Noteworthy, some gene ontology (GO) terms enriched in T. gondii DRPS13 -Tc are also 980 
overrepresented in the P. cynomolgi hypnozoite (stars in Fig. 6D). Further, without ATc the 981 
transcriptome of T. gondii DRPS13 is compatible with a parasite transitioning from an active 982 
replicating form to a dormant stage, reflected by the downregulation of genes typical of the S and 983 
M stages of the cell cycle, and of genes that participate in energy metabolism and virulence (Fig. 984 
6B, D, and Supplemental Table S2 and Fig S2). It has been reported that with treatment of active 985 
forms of malaria, hypnozoites still persist, and recrudesce later (Cubi et al, 2017, Hutson et al 986 
2010; St.Jean et al, 2016; Lacerda et al, 2019; Llanos-Cuentas et al, 2019). Also, compounds that 987 
target cytochrome b/c were not effective against malaria hypnozoites. If primaquine or 988 
tafenoquine, which do not treat the active P.vivax parasites, were added in vivo, hypnozoites have 989 
been shown not to recrudesce, or do so less often (St. Jean et al, 2016; Lacerda et al, 2019; Llanos-990 
Cuentas et al,2019).  Testing with primaquine or tafenoquine could only be performed in vivo, as 991 
activity against the hypnozoite requires hepatic metabolism of primaquine or tafenoquine (St.J ean 992 
et al 2016;Lacerda et al, 2019; Llanos-Cuentas et al,2019). Tafenoquine is not active in tissue 993 
culture which is consistent with the findings that these compounds require hepatic metabolism. To 994 
establish a parallel in vivo system, we studied immune compromised mice (Interferon ¡ receptor 995 
knockout mice with the knockout in the germline) infected with DRPS13 herein. Although in 996 
immune competent mice DRPS13 does not recrudesce with ATc treatment beyond 3 days after 997 
infection, we found that when ATc was added after treatment of the immune compromised mice 998 
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with JAG21 dosed intraperitoneally for 14 days, the dormant DRPS13 parasite could still 999 
recrudesce after JAG21 treatment was discontinued and tetracycline added (Fig. 6C, 1000 
Supplemental Fig. S2). Consistent with adding tafenoquine to treatment of P.vivax malaria with 1001 
chloroquine where both medicines together were partially effective against the active and 1002 
hypnozoite forms, the combination of JAG21 and tafenoquine had a modest effect together on 1003 
transiently improving survival time when ATc was added when compared with JAG21 or 1004 
tafenoquine alone (Fig 6C, Supplemental Fig. S2). The trend in the result seems similar to the 1005 
malaria infections where hypnozoites form, although protection was not as robust, as in the malaria 1006 
model, and we did not achieve complete, durable protection against DRPS13. These results in 1007 
Figures  6C and S2 suggest: a. In G1 arrested organisms that begin as tachyzoites, they can persist 1008 
in vivo even if their morphology as parasites is difficult to discern; b. Treatment with 1009 
JAG21+Tafenoquine can prolong time to death more robustly than other treatments; c. But, in 1010 
these immune compromised mice at this dosage regimen this treatment did not robustly, durably 1011 
protect these mice from death later; d. In these immune compromised mice, whether this lack of 1012 
complete protection was because of immune compromise, or less than optimal duration of 1013 
treatment, or suboptimal dose or timing of treatments, or that this G1 arrested organism is harder 1014 
to treat, remains to be determined in future studies. The modest efficacy of the two compounds, 1015 
administered together, suggests that treating both tachyzoites and the G1 arrested organisms is 1016 
important. This seems similar to P. cynomogli and P. vivax treatment with tafenoquine and 1017 
chloroquine studies, which also showed efficacy but was not completely successful in preventing 1018 
relapse. At the time this study was performed, formulation and dosing (including duration and 1019 
timing) had not yet been optimized formally for the T.gondii model. P. vivax treatment requires 1020 
chloroquine to treat blood schizonts and tafenoquine to treat hypnozoites. Treatment in man, per 1021 
the FDA approved label, consists of a single dose of 300 mg on day 1 co-administered with 1022 
chloroquine treatment on days 1 or 2. Both medicines have long half-lives in humans. This 1023 
treatment was relatively effective in humans, with about a 30% recurrence rate.  1024 
        Sinai et al have demonstrated heterogeneity in the phenotypes of organisms within established 1025 
cysts. Their work found bradyzoites within cysts are not uniform with regard to their replication 1026 
potential (Watts et al, 2015), mitochondrial activity (Sinai, unpublished), and levels of the glucose 1027 
storage polymer amylopectin (Sinai, unpublished). These properties of bradyzoites within (Watts, 1028 
et al, 2015), and properties of tissue cysts vary during the course of infection with unappreciated 1029 
levels of complexity in the progression of chronic toxoplasmosis (Watts et al, 2015).  The analysis 1030 
(Fig 6D) of the DRPS13 infected NSC suggests molecular targets modified in this G1 arrested 1031 
DRPS13 parasite as shown in Fig 6D Supplemental Table S2. In the future, with formulation and 1032 
pharmacokinetics of JAG21  optimized, it will be of interest to determine whether JAG21 can 1033 
eliminate these organisms and any residual structures as in Fig6C, or whether adding synergistic 1034 
compounds such as atovaquone (Fig 4B) or antisense effective against these upregulated molecular 1035 
targets, such as kinases, ATPases, AP2s (Fig 6D and Table S2), or a newly recognized bradyzoite 1036 
master regulator of differentiation might be effective alone or might be synergistic with JAG21 1037 
against this DRPS13, as well as the conventional recognized tachyzoite and bradyzoite life cycle 1038 
stages.  Chen et al reported in the transcriptomes of established bradyzoite in vivo cysts that 1039 
EIF2kinase of stressed parasites is present ( Chen et al, 2018), but we have not found other overlap 1040 
of Chen’s transciptome with P cynomogoli or DRPS13 transcriptomes.  Others have described 1041 
EIF2kinase and stress granules only in transitioning or extracellular parasites (Watts et al, 2015). 1042 
Bradyzoites within tissue cysts are not monolithic, so in future studies single cell RNA sequencing 1043 
of bradyzoites obtained by laser capture of bradyzoites in vivo defined on the basis of their 1044 
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physiological state, may be needed to determine whether a transcriptome signature similar to 1045 
DRPS13 is sometimes present, linked to morphologic/immunostaining features that might 1046 
functionally distinguish them to define the character of a hypnozoite-like state in T.gondii. We 1047 
noted hererogeneity of parasite phenotype, even in the same vacuoles In our earlier IFA and 1048 
electron microscopic characterization of G1 arrested DRPS13 in HFF (Hutson et al, 1049 
2010).  Heterogeneity also was found very recently in tachyzoites and bradyzoites created by 1050 
alkaline conditions in culture across the cell cycle in vitro in HFF, using single cell RNA 1051 
sequencing (Xue et al  Biorx, 6/3/2019 In Press). These authors also noted that what had 1052 
been interpreted as “noise” earlier was found actually to be signal in a more complex environment. 1053 
These authors suggest that such heterogeneity might make developing curative treatments more 1054 
complex.  Our analysis of JAG21 effects and the DRPS13-ATet knockdown herein begin to help 1055 
address this question: We noted that consistent with heterogeneity in our IFAs, in our comparison 1056 
with the Xue et al’s heterogeneous   P1-6 clusters analysis, we found that most of the up- or down-1057 
regulated genes are within P3-P5 tachyzoite clusters. Also, consistent with the heterogeneity we 1058 
observed in our G1 arrested  DRPS13 -ATet comparison, DRPS13 has a drop in SAG1 and elevated 1059 
SRS44 that is consistent with a brady-like phenotype. BAG1 expression was too low overall to 1060 
draw any conclusion about BAG1. It is also noteworthy that in our -ATet relative to +Atet 1061 
conditions in primary, human, brain, neuronal stem cells, the master regulator of bradyzoite 1062 
differentiation is slightly overexpressed (Log2 Fold Change=0.7, adjusted p-value=0.043). 1063 
Although JAG21 is highly potent against tachyzoites and bradyzoites, it did not eliminate every 1064 
long-established encysted bradyzoite or -ATet DRPS13 completely either in vitro or in IFNg 1065 
knock-out mice in vivo.  Consistent with heterogeneity, herein JAG21 treatment of DRPS13 and 1066 
transcriptomics analyses define a metabolically quiescent, persister,“stasis” state that is reversible 1067 
even after substantial periods of dormancy, that contribute to conceptual and functional 1068 
understanding of both Plasmodia species and T. gondii infections and molecular mechanisms 1069 
whereby “persisters” might be eliminated. 1070 
 1071  1072 
An oral nanoformulation is potent against virulent RH 1073 
To further develop JAG21 for practical, clinical use, our next step was to make a formulation that 1074 
is stable at room temperature, and would be effective when administered orally: Following a 1075 
number of unsuccessful alternative methods (data not shown, a dispersion of JAG21 was prepared 1076 
using hydroxyethyl cellulose (HEC) and Tween 80. This new formulation method  is described in 1077 
the Materials and Methods. When this dispersion was imaged using a Nikon ECLIPSE E200 1078 
optical microscope set to 40x magnification, the average particle size of the JAG21 dispersion in 1079 
HEC/Tween 80 was determined using an in-house image analysis program and was found to be 1080 
2.85µm (Fig. 7A). Material was re-sonciated the same way just prior to administration after being 1081 
stored for 6 months and retained the same properties (Fig 7A) when imaged. Following 1082 
administration of 2,000 highly virulent RH Strain tachyzoites intraperitoneally, the oral 1083 
nanoformulation was administered by gavage using a 21 gauge needle. This was given either (1) 1084 
as a single dose of 5, 10, or 20mg/kg, or (2) three daily doses of 10mg/kg given for the first three 1085 
days after infection. After 5 days the RH strain tachyzoites in peritoneal fluid of each mouse were 1086 
quantitated by measurement of YFP they expressed using a flurimeter and by quantitating parasites 1087 
present in peritoneal fluid using a hemocytometer. Parasite burden was reduced by ~60% 5 days 1088 
later following the single doses of 10 and 20mg/kg (representative experiment with 10mg/kg 1089 
shown in Fig.7B; p<0.03) and markedly reduced with three doses of 10mg/kg administered on 1090 
each of the first three days after intraperitoneal injection of the virulent RH strain tachyzoites 1091 
I r vi
ew
	 27	
(Fig.7C, representative experiment, p<0.001). This is the proof of principle that will facilitate 1092 
media milling, dispersant, and a self disintegrating tablet in the future. JAG21 has real promise as 1093 
a mature lead compound to treat both T.gondii and Plasmodium species infections. 1094 
 1095  1096 
DISCUSSION 1097 
 1098 
T.gondii infections are highly prevalent and the impact of this disease can be devastatingly severe. 1099 
Current treatments have toxicity or hypersensitivity side effects.  New compounds that are without 1100 
toxicity or hypersensitivity, and that are highly active against tachyzoites would be of considerable 1101 
clinical usefulness. Further, no medicines are active against the encysted stage or definitively 1102 
curative. In addition, malaria is lethal for 1 child every eleven seconds and a threat to travelers 1103 
going to endemic areas. Development of drug resistance also increases the need for new anti-1104 
malarial compounds. Our goal in this work herein was to identify compounds highly effective 1105 
against T . gondii and P. falciparum, and we believe we have achieved our goal by developing lead 1106 
compounds with dual activity. 1107 
         To further develop the THQ series, 54 compounds were synthesized to improve kinetic 1108 
solubility, solubility in physiologically-relevant media (FaSSIF, FeSSIF), and metabolic stability 1109 
(microsomes and hepatocytes), and other ADMET properties. Compounds JAG050 and JAG021 1110 
were identified as lead compounds, demonstrating potent inhibition on both tachyzoites and 1111 
bradyzoites life stages and were not toxic to human cells in our in vitro model (HFF).  In addition, 1112 
both compounds displayed low nanomolar efficacy against multiple drug resistant strains of P. 1113 
falciparum in vitro. JAG050 and JAG021 demonstrate promising ADMET properties, with JAG21 1114 
slight superior due to the compound's longer metabolic stability in human and mouse microsomes. 1115 
        A striking result with JAG21 in our in vivo parasite studies is the compound's high efficacy 1116 
against T.gondii tachyzoites and bradyzoites.  In our P. berghei in vivo model for malaria, we 1117 
observed that a single dose causal prophylaxis in 5 C57BL/6 albino mice at 2.5 mpk dosed on day 1118 
0, 1 hour after intravenous administration of 10,000 P. berghei sporozoites was achieved. Causal 1119 
prophylaxis was also observed after a 3-dose treatment in 5 C57BL/6 albino mice at 0.6 mpk dosed 1120 
on days -1, 0, and +1. A representative figure at a higher dose (5 mg/kg) is shown, and all 1121 
experiments with the amounts mentioned above demonstrated identical high efficacy in 1122 
luminescence, parasitemia, and survival results. This demonstrates that JAG21 functions better in 1123 
this in vivo model than the ELQ 300 series where prodrug formulation is required to achieve 1124 
solubility and efficacy In contrast to the efficacy of JAG21 at 2.5mg/kg in a single oral dose model 1125 
resulting in cure without a prodrug. ELQ 300 (not the prodrug) was not effective at doses between 1126 
1 and 20 mg/kg although the prodrug was more effective (Doggett, et al 2012); Freuh et al, 2017). 1127 
        JAG050 and JAG021 are lead compounds, with JAG21 being a superior compound due to its 1128 
favorable predicted ADMET properties, potency, efficacy and lack of toxicity. JAG021 1129 
demonstrates increased solubility and potential for advanced formulation.  There also is potential 1130 
for improving solubility and reducing toxicity further because of the larger binding pocket in the 1131 
apicomplexan Cytbc1 enzyme compared with the mammalian Cytbc1 enzyme, determined by 1132 
modeling occupancy of the structure, enzyme assays and empirically, if it were needed. We have 1133 
created and tested additional compounds that take advantage of these properties, although none at 1134 
present, have the proven ADMET and marked in vivo efficacy we found to be advantages in our 1135 
proof of principle studies of JAG21. At present, however, our mature lead compound has sufficient 1136 
drug like properties to move to advanced formulations, suggesting increased bulk will not be 1137 
needed to reduce toxicity. It has selectivity as demonstrated by our enzymatic, binding and 1138 
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structure studies, although there are additional compounds that show even greater selectivity. It is 1139 
highly effective in an oral nano preparation against P. berghei three life cycle stages, and with 1140 
early treatment appears to be capable of curing toxoplasmosis in immunocompetent mice. This 1141 
work demonstrates the promising nature of this novel tetrahydroquinolone scaffold and mature 1142 
lead compound. JAG21 has the potential to become an orally administered medicine or with 1143 
partners, part of a medicine combination that is curative for toxoplasmosis and is a single dose 1144 
cure for malaria. It is suitable for partnering with other compounds to obviate problems with 1145 
selection of resistant mutants. We have demonstrated earlier that the parent compound with this 1146 
new scaffold is synergistic with atovaquone and additive with cycloguanil (in proguanil) against 1147 
P. falciparum (McPhillie et al, 2016). This compound is a mature lead compound to treat both 1148 
T.gondii and Plasmodium species infections. If utility and safety is retained and no toxicity appears 1149 
in next stage studies, this compound may become suitable for treatment of T. gondii and P. 1150 
falciparum infections.  1151 
 1152 
CONCLUSION  1153 
 1154 
JAG21 has real promise as a mature lead compound to treat both T.gondii and Plasmodium species 1155 
infections, demonstrated in vitro and in vivo. It has high efficacy against T.gondii tachyzoites and 1156 
bradyzoites, and established encysted organisms. Treatment with a single low oral dose is effective 1157 
for causal prophylaxis and radical cure of P.berghei infections. JAG 21 has complete efficacy 1158 
against three life cycle stages of P.berghei. In terms of companion inhibitors, JAG21, a Qi 1159 
inhibitor, synergizes against tachyzoites with atovaquone (a Qo inhibitor) in vitro.  It appears able 1160 
to contribute modestly to protection of immune compromised mice in conjunction with 1161 
tafenoquine against an initially replicating, then G1 arrested, T.gondii parasite that shares key 1162 
transcriptomic components with P. cynomolgi hypnozoites. Our mature lead compound has 1163 
sufficient selectivity and drug-like properties to support ongoing efforts to further develop this 1164 
compound through preparation of advanced formulations and testing of additional study of 1165 
pharmacokinetics, efficacy and safety.  1166 
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FIGURE LEGENDS 1435 
Figure 1. Characteristics and effects of compounds on inhibition of  T.gondii replication and 1436 
enzyme activity, and Structure Activity Relationship analysis.  A. Cytochrome b/c inhibitor 1437 
code, Chem Draw structure, solubility in PBS 7.4, toxicity against HFF, predicted half-life, 1438 
and inhibitory effect of compounds on RH strain tachyzoites and EGS strain bradyzoites in 1439 
vitro. and saffarine O assay enzyme activity. PBS Sol/Toxicity pH7.4 refers to solubility of the 1440 
compound in Phosphate Bufferred Saline (PBS) at pH7.4. Toxicity refers to the highest 1441 
concentration tested that does not show toxicity to Human Foreskin Fibroblast (HFF) in tissue 1442 
culture in WST assay; T1/2 (H) refers to the predicted half-life in human liver microsomes; T1/2 1443 
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(M) refers to the predicted half-life in mouse liver microsomes. Tachy/Brady IC50 was determined 1444 
in studies in which cultures of parasites in HFF were treated with varying concentrations of the 1445 
compound and there was 50% inhibition of the replication (number) of parasites. Parasites were 1446 
RH-YFP expressing tachyzoites (Tachy) and EGS (Brady) strains. Studies of effects of inhibitors 1447 
on HFF or on T.gondii tachyzoites were performed with triplicate wells in at least 2 biological 1448 
replicate experiments. Studies of effects on bradyzoites were performed at least twice in at least 2 1449 
biological replicate experiments. Compounds with much less inhibition of mammalian than T. 1450 
gondii cytochrome bc in the saffarine enzyme assay (indicated by **) provide potential to further 1451 
develop compounds, if unanticipated toxicity occurs from JAG21.  B. Structure Activity 1452 
Relationship analysis (SAR).  The effects of changing R1 as 7-Et, 7-Me, 6-CF3, or 6-Me on 1453 
activity against T.gondii RH strain tachyzoites, solubility, and stability were compared in the SAR.  1454 
Colour Key in B: Activity: Green <50 nM, Red > 1 µM; Solubility in 100 mM Phosphate Buffer 1455 
(pH 7.4): Amber>10 µM, Red <10 µM; Metabolic Stability: Green >120 mins, Amber 60-120mins, 1456 
red < 60 mins. SAR panel displays only representative structures and trends within the JAG 1457 
compound series. JAG21 (blue font) is highly active, has the longest predicted half-life for humans 1458 
of initial compounds tested (green), combined with improved solubility, no hERG liability, and 1459 
predicted capacity to cross the blood brain barrier (BBB). Definitions of ADMET terminology are 1460 
in the Materials and Methods. In summary, in the SAR overall, nitrogen atoms not tolerated in aryl 1461 
ring (C) and the 4-position was optimal for phenol substituent  1462 
 1463 
Figure 2. JA21 is potent in vitro against T. gondii, tachyzoites and bradyzoites, and multiple 1464 
drug resistant strains of P. falciparum   A. JAG is effective Against RH-YFP tachyzoites, and 1465 
does not harm human cells. Potent effect of JAG 50 is also shown.  A representative experiment 1466 
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is shown.  N=triplicate wells in at least 2 biological replicate experiments. Relative fluorescence 1467 
units are shown on vertical axis, where decrease in fluorescence compared to diluent  DMSO in 1468 
media control indicates parasite inhibition. Horizontal axis indicates different treatment 1469 
conditions: This shows results of testing of fibroblasts in media (HFF), DMS0 control, positive 1470 
control pyrimethamine (P) and sulfadiazine(S), and concentrations of JAG21 and JAG50 utilized.  1471 
Differences were not statistically significant in the cytotoxicity assay (data not shown),.   B. 1472 
JAG21 is effective against EGS bradyzoites. Effect of JAG21 in reducing bradyzoites in HFF 1473 
by parasite strain EGS. HFF were infected by EGS and treated with JAG21 at concentrations 1474 
indicated. Slides were stained with Dolichos Biflorus Agglutinin conjugated with FITC (which 1475 
stains the cyst wall) and DAPI, and observed with fluorescence microscopy. The red arrows point 1476 
to the Dolichos enclosed organisms formed in tissue culture. These were eliminated with treatment 1477 
with JAG21. This experiment was performed >4 times. These experiments were performed with 3 1478 
different observers reviewing slides at the microscope  quantitating  fields for each  condition. 1479 
Slides were also scanned and the scans of the slides were reviewed so all fields in the entire slide 1480 
were noted to be consistent . C.  Synergy of JAG21 and atovaquone against Rh-YFP 1481 
tachyzoites in vitro. Isobologram comparing JAG21, atovoquone, and JAG21 plus atovaquone 1482 
demonstrates synergy. D. THQs effective against drug resistant P. falciparum. Dose-response 1483 
phenotypes of a panel of P. falciparum parasite lines. IC50 values were calculated using whole-cell SYBR 1484 
Green assay and listed as mean +/- standard deviation of three biological replicates, each with triplicate 1485 
measurements. The D6 strain is a drug sensitive strain from Sierra Leone, the TM91-C235 strain is a multi-1486 
drug resistant strain from Thailand, the W2 strain is a chloroquine resistant strain from Thailand, and the 1487 
C2B strain is a multi-drug resistant strain with resistance against atovaquone.    E. Solubility and Stability 1488 
in human and mouse liver microsomes comparing  MJM 170, JAG21 and JAG50.  Performed by Chem 1489 
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Partners. F. JAG21 CYP450 Inhibition, CACO-2, hERG, PPB, BBB (MDCK-MDK1 efflux analyses. 1490 
These were performed by Chem Partners and are as defined in the Materials and Methods.. 1491 
 1492 
Figure 3. Effect of JAG21, and other THQ compounds on mitochondrial functions of. T.gondii 1493 
and. P. falciparum and HFF-hTERT A. Maximum mitochondrial membrane depolarization of 1494 
JAG21, JAG39, JAG46, JAG47, JAG50 and Atovaquone (4 µM) and FCCP (5 µM).  Digitonin 1495 
was added where indicated by the arrow to permeabilize cells and permit a necessary mitochondrial 1496 
substrate (Succinate) to reach intracellular organelles. The addition of the indicated compounds is 1497 
shown by the second arrow. B. Quantification of the depolarization shown in A. The relative 1498 
depolarization of each compound was normalized to the depolarization by FCCP which was 1499 
considered 100% depolarization. C. Effect of various concentrations of JAG21 and Atovaquone 1500 
on the mitochondrial membrane potential measured as in A. The first arrow indicates digitonin 1501 
addition and the second arrow indicates the addition of compounds at the specified concentration. 1502 
D. Quantification of the depolarization measured in C. The relative depolarization of each 1503 
compound was normalized to the depolarization by FCCP (100%). E. Mitochondrial membrane 1504 
depolarization of HFF-hTERT in suspension by JAG21 and atovaquone. The first arrow indicated 1505 
the addition of digitonin, and the second arrow indicates addition of the indicated compounds at 1506 
the indicated concentration. F. Quantification of the depolarization measured in E. The relative 1507 
depolarization of each compound was normalized with the depolarization by FCCP, which was 1508 
considered 100%. B, D, E X+/-S.D., N=3 independent experiments. Statistical analysis (unpaired 1509 
student t test) was performed using GraphPad Prism 8.0 (GraphPad Software, Inc., San Diego, 1510 
CA). **. P < 0.01. ***. P < 0.001. g. JAG21, JAG99 and MJM210 (1 µM) inhibited P. falciparum 1511 
cytochrome c reduction. Vehicle (DMSO)/atovaquone (1 µM) were negative/positive controls, 1512 
1290 respectively. X+/-S.D., N=4 independent experiments. 1513 
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 1514 
Figure 4. Binding studies of JAG021 to bovine bc1.  A. Bovine Cytbc1 activity assays showing 1515 
36% and 63% inhibition at  0.1 and 1µM concentration of JAG021, respectively. N= at least 2 1516 
biological replicate experiments with similar results. B. The Cytbc1 structure presented in cartoon 1517 
style with clear omit (Fo-Fc) electron density map for the bound JAG021 compound only in the 1518 
Qi site showing selectivity within the binding pocket. Qi and Qo sites are marked by 1519 
black ellipsoids. C. The bound JAG021 compound (orange) within the Qi site with 1520 
corresponding (2Fo-Fc) electron density map contoured at 1 σ level as grey mesh. The residues 1521 
which make close interactions with the bound inhibitor are shown in stick format and labelled. 1522 
D. 2D pharmacophore analysis of JAG021 binding pocket produced using Ligplot+ LS-2011. 1523 
Hydrophobic interactions are shown as red spikes, hydrogen bond with Ser35 is shown by green 1524 
dashes. E.  Cryo-EM derived structure of the Cytbc1 bound JAG021 structure with corresponding 1525 
density map contoured at 3 σ level suggesting two different positions for the head group 1526 
represented by two regions of density shown as yellow mesh. The Cytbc1 structure bound to the 1527 
pyridone GSK932121 (PDB:4D6U) (F) and quinolone MJM170 (PDB:5NMI) (G) in the Qi site. 1528 
Haem and compounds are shown as colored sticks, Fe ion as orange sphere and hydrogen bonding 1529 
as black lines. Hydrogen bonding with Ser35 is shown as black dashes. 1530 
 1531 
Figure 5 . JAG21 is a mature lead that protects against T.  gondii and P.berghei in vivo. A.  1532 
JAG21 treatment for 14 days protects against T.gondii tachyzoites in vivo. Tachyzoite 1533 
challenge with Prugneaud luciferase parasites imaged with leuciferin using IVIS demonstrates that 1534 
treatment with JAG21 eliminates leuciferase expressing parasites and leads to 100% survival of 1535 
JAG21 treated infected  mice.  No cysts were found in brains of mice at 30 days after infection 1536 
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when they have been treated with JAG21 for the first 14 days after infection. There were 2 1537 
biological replicate experiments with 5 mice per group with similar results.  B. JAG21 and JAG21 1538 
plus tafenoquine markedly reduce Me49 strain brain cyst numbers in vivo in Balb/C mice at 1539 
30 days after infection. Parasites were quantitated by scanning the entire immunoperoxidase 1540 
stained slide in an automated manner and by two observers blinded to the experimental treatment 1541 
using  microscopic evaluation.  In each of two experiments, the numbers of mice per group were 1542 
as follows: Experiment 1 had  4 diluent controls,  5 JAG21,  4 JAG21/Tafenoquine  treated mice; 1543 
and Experiment 2 had 5 diluent controls,  5 JAG21, 3 JAG21/Tafenoquine treated 1544 
mice.   Immunoperoxidase staining was performed. Parasite burden was quantitated using a 1545 
positive pixel count algorithm of Aperio ImageScope software. Positive pixels were normalized to 1546 
tissue area (mm2). Quantification was by counting positive pixels per square area.  The entire brain 1547 
in one section was scanned for each mouse.   The parasite burden was quantitated as units of 1548 
positive pixels per mm2.  The  average +/- S.E.M. numbers of mm2 per slide quantitated 1549 
was  30.2+/-1.6 mm2 per mouse for this quantification.   Each high power field of view shown in 1550 
C is approximately 0.02 mm2 per field of view. A representative single experiment is presented 1551 
and the data from the two experiments analyzed together also demonstrated significant differences 1552 
between the untreatated and treated groups (p<0.01; Supplemental Fig. S1.). C. Microscopic 1553 
evaluation of the slides reveal effect of JAG21 and JAG21 plus tafenoquine having the same 1554 
pattern as the automated quantitation of immunoperoxidase stained material. There are usual 1555 
appearing cysts in the DMSO control untreated mice as shown in the top panels, and rare cysts in 1556 
the treated mice with most of the brown material appearing amorphous (bottom panels). D. JAG21 1557 
nanoformulation dosages administered to P.berghei infected C57Bl6/albino mice compared 1558 
with vehicle control. Design of single dose and 3 day dose experiments.  E. JAG21 1559 
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nanoformulation cures P.  berghei sporozoites(c), blood(d) and liver stages(e) with oral 1560 
administration of a single dose of 2.5mg/kg or 3 doses at 0.625mg/kg.  Single dose causal 1561 
prophylaxis in 5 C57BL/6 albino mice at 2.5 mpk dosed on day 0, 1 hour after intravenous 1562 
administration of 10,000 P. berghei sporozoites. Shown is 3 dose causal prophylaxis treatment in 1563 
5 C57BL/6 albino mice at 0.625 mpk dosed on days -1, 0, and +1. Representative figure showing 1564 
survival, luminescence and parasitemia quantitated by flow cytometry for 5 mg/kg.  1565 
 1566 
Figure  6. T. gondii ∆RPS13 transcriptome during  Primary Human Brain Neuronal Stem 1567 
Cell (NSC) infection and in-vivo susceptibility to JAG21 and TAF treatment are reminiscent 1568 
of literature findings with malaria hypnozoites. A, P. cynomolgi-T. gondii best reciprocal match 1569 
genes significantly upregulated (red) or downregulated (blue) in P. cynomolgi hypnozoites 1570 
compared to liver-schizont stage and in ∆RPS13  after downregulation of rps13 gene expression 1571 
(p-value ≤ 0.05, FDR ≤ 0.2). B, Gene-set enrichment analysis of ∆RPS13 +/-Tc. Blue and red 1572 
nodes denote gene-sets enriched in presence or absence of Tc respectively. Node diameters are 1573 
proportional to number of genes belonging to corresponding gene-sets. Edge thickness is 1574 
proportional to number of genes shared between connected nodes.  C, Survival rate of mice 1575 
infected with 100,000 ΔRPS13 followed by treatment with diluent, JAG21, tafenoquine (TAF) or 1576 
the two together (JAG21/TAF). Then tetracycline was added at 14 days. The combination of the 1577 
two compounds resulted in improved time of survival (p<0.03, Experiment 1;p=0.08 Experiment 1578 
2, p=0.002 Experiment 1+2). The full data are presented in the box below the image in Fig 6C. In 1579 
6C, Rx refers to treatment of mice with diluent (DMSO), Tafenoquine (TAF), or JAG21, or JAG21 1580 
and TAF. DRPS13 is referred to as RhRPS13D in the title of the box in Fig 6C. In Supplemental 1581 
Fig.S2, histological preparations that are immunoperoxidase stained for T gondii antigens from a 1582 
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pilot study were prepared (Supplemental Fig. S2). These are images, in Fig S2 of liver and spleen 1583 
from IFN g receptor knock out mice without treatment on days 7 and 14 after infection. In those 1584 
mice without any treatment there was amorphous brown immunoperoxidase stained material in 1585 
Fig S2 A. When tetracycline (aTet) was administered on day 14 after infection in drinking water 1586 
on day 14 and tissues obtained and immunostained for T. gondii antigens from mice that died or 1587 
became very ill, organisms clearly recognizable could be seen (Supplemental Fig S2B-E).  Design 1588 
of the treatment experiment with control DMSO diluent, JAG21 alone, Tafenoquine alone (TAF) 1589 
or the two together (JAG/TAF) with full data for each of the groups and with the composite 1590 
analysis from replicate experiments, including numbers of mice, are shown in supplemental Fig. 1591 
S2C, D.   Fig S2 C, D shows prolongation of survival time, but there is not durable protection 1592 
against ∆RPS13 in these immune compromised mice treated with JAG21/TAF as described. This 1593 
is summarized in C to demonstrate early prolongation of survival time with the detailed data in 1594 
Fig S2.  D. Gene ontology enrichment analysis of ∆RPS13 +/-Tc. Node and edge conventions 1595 
are the same as in B. There were at least 2 biologic replicates of each experiment. 1596 
 1597 
Figure 7. Oral nanoformulation of JAG21 potently protects against 2000 highly virulent RH 1598 
strain tachyzoites given intraperitoneally.  A. Folllowing sonication produces nanoparticles of 1599 
~2.86microM.  B. Single oral dose of 10mg/kg reduced intraperitoneal tachyzoites measured by 1600 
RH YFP expression and counting with hematocytometer(p<0.03),,  C. Three daily 10mg/kg doses 1601 
markedly and significantly reduces  intraperitoneal parasite burden measured as fluorescence and 1602 
by hematocytometer on the fifth day(p<0.001).No compound was administered after the third day. 1603 
N=at least 2 biological replicate experiments with 5 mice per group with similar results.                                                                                                                                                                                           1604 
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